<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="prp21078" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="pmc-domain-id">2563</journal-id><journal-id journal-id-type="pmc-domain">pharmrespersp</journal-id><journal-id journal-id-type="publisher-id">PRP2</journal-id><journal-title-group><journal-title>Pharmacology Research &amp; Perspectives</journal-title></journal-title-group><issn pub-type="epub">2052-1707</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10073930</article-id><article-id pub-id-type="pmcid-ver">PMC10073930.1</article-id><article-id pub-id-type="pmcaid">10073930</article-id><article-id pub-id-type="pmcaiid">10073930</article-id><article-id pub-id-type="pmid">37016811</article-id><article-id pub-id-type="doi">10.1002/prp2.1078</article-id><article-id pub-id-type="publisher-id">PRP21078</article-id><article-id pub-id-type="other">PRP2-2023-02-0069</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Risk of antidepressant initiation among users of cardiovascular agents and metformin.</article-title><subtitle>Findings from the Tr&#248;ndelag Health Study (<styled-content style="fixed-case" toggle="no">HUNT</styled-content>) and Norwegian Prescription Database (<styled-content style="fixed-case" toggle="no">NorPD</styled-content>), Norway</subtitle><alt-title alt-title-type="left-running-head">Bojani&#263; et al.</alt-title></title-group><contrib-group><contrib id="prp21078-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Bojani&#263;</surname><given-names initials="I">Ivana</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2609-7536</contrib-id><xref rid="prp21078-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="prp21078-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>ivana.bojanic@nord.no</email></address></contrib><contrib id="prp21078-cr-0002" contrib-type="author"><name name-style="western"><surname>Bjerkeset</surname><given-names initials="O">Ottar</given-names></name><xref rid="prp21078-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="prp21078-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="prp21078-cr-0003" contrib-type="author"><name name-style="western"><surname>Williams</surname><given-names initials="LJ">Lana J.</given-names></name><xref rid="prp21078-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="prp21078-cr-0004" contrib-type="author"><name name-style="western"><surname>Berk</surname><given-names initials="M">Michael</given-names></name><xref rid="prp21078-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="prp21078-cr-0005" contrib-type="author"><name name-style="western"><surname>Bj&#248;rngaard</surname><given-names initials="JH">Johan H&#229;kon</given-names></name><xref rid="prp21078-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="prp21078-cr-0006" contrib-type="author"><name name-style="western"><surname>Sund</surname><given-names initials="ER">Erik R.</given-names></name><xref rid="prp21078-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="prp21078-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="prp21078-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="prp21078-cr-0007" contrib-type="author"><name name-style="western"><surname>Sletvold</surname><given-names initials="H">Hege</given-names></name><xref rid="prp21078-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="prp21078-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Faculty of Nursing and Health Sciences</named-content>
<institution>Nord University</institution>
<city>Levanger</city>
<country country="NO">Norway</country>
</aff><aff id="prp21078-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Public Health and Nursing, Faculty of Medicine and Health Sciences</named-content>
<institution>Norwegian University of Science and Technology, NTNU</institution>
<city>Trondheim</city>
<country country="NO">Norway</country>
</aff><aff id="prp21078-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Mental Health, Faculty of Medicine and Health Sciences</named-content>
<institution>Norwegian University of Science and Technology, NTNU</institution>
<city>Trondheim</city>
<country country="NO">Norway</country>
</aff><aff id="prp21078-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">IMPACT &#8211; the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health</named-content>
<institution>Deakin University</institution>
<city>Geelong</city>
<country country="AU">Australia</country>
</aff><aff id="prp21078-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">HUNT Research Centre, Department of Public Health and Nursing, Faculty of Medicine and Health Science</named-content>
<institution>Norwegian University of Science and Technology, NTNU</institution>
<city>Levanger</city>
<country country="NO">Norway</country>
</aff><aff id="prp21078-aff-0006">
<label>
<sup>6</sup>
</label>
<institution>Levanger Hospital, Nord&#8208;Tr&#248;ndelag Hospital Trust</institution>
<city>Levanger</city>
<country country="NO">Norway</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Ivana Bojani&#263;, Faculty of Nursing and Health Sciences, Nord University, PB 93, 7601 Levanger, Norway.<break/>
Email: <email>ivana.bojanic@nord.no</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>11</volume><issue seq="200">2</issue><issue-id pub-id-type="pmc-issue-id">429343</issue-id><issue-id pub-id-type="doi">10.1002/prp2.v11.2</issue-id><elocation-id>e01078</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>01</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>06</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-11 04:10:11.273"><day>11</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2023 The Authors. <italic toggle="yes">Pharmacology Research &amp; Perspectives</italic> published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PRP2-11-e01078.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PRP2-11-e01078.pdf"/><abstract><title>Abstract</title><p>Cardiovascular disease and diabetes are risk factors for depression, yet the relationship between the drug treatments for these diseases and the risk of antidepressant initiation remains unclear. This study aimed to examine possible associations between the use of angiotensin II receptor blockers (ARBs), angiotensin&#8208;converting enzyme inhibitors (ACEI), acetylsalicylic acid (ASA), beta&#8208;blockers (BB), calcium channel blockers (CCB), diuretics, or metformin and risk of antidepressant initiation. The Tr&#248;ndelag Health Study (HUNT3), Norway, was linked to the Norwegian Prescription Database (NorPD). Participants with no prescriptions of cardiovascular agents, metformin, or antidepressants for at least 6&#8201;months before HUNT3 (baseline) were eligible and followed for 10&#8201;years. The exposure was the use of cardiovascular agents or metformin, defined as mono&#8208; or polytherapy from baseline to end of follow&#8208;up. The outcome was the initiation of antidepressant use, indicated by the first drug dispensation during the study period and expressed as hazard ratios (HRs) with 95% confidence intervals (CI). Among 20&#8201;227 adults aged 40&#8211;70&#8201;years at baseline, we observed different associations between cardiovascular agents or metformin and the risk of antidepressant initiation. ARBs or CCB monotherapy was associated with a lower risk of initiating antidepressant use (HR 0.70; 95%CI 0.56&#8211;0.88 and HR 0.81; 95%CI 0.61&#8211;1.06, respectively) compared to no use of any drugs included in the study (reference). Reduced risk of antidepressant initiation was among ASA or statin polytherapy users, whereas there was a small increased risk among participants on ASA monotherapy. In contrast, there was no statistical evidence of associations between ACEI, BB, diuretics, or metformin and increased or decreased risk of antidepressant initiation. Our mixed findings indicate the possibility that some cardiovascular agents may be associated with a reduced risk of initiating antidepressant use while others may not. However, bias due to the limitations of the study design is possible.</p></abstract><abstract abstract-type="graphical"><p>Adjusted Hazard Ratios (HRs) with 95% confidence intervals (CIs) for the initiation of antidepressant use according to cardiovascular agents and metformin mono&#8208; or polytherapy during a 10&#8208;ten year follow&#8208;up. Participants with no dispensed prescriptions for metformin or any cardiovascular agents included in this study as a reference.ACE&#8208;I = Angiotensin&#8208;converting enzyme inhibitors; ARBs = Angiotensin II receptor blockers; ASA= AcetylsalicylicAcid; BB = Beta&#8208;blockers; CCB = Calcium channel blockers.The adjustment was carried out for age as a time&#8208;varying covariate, sex, HADS&#8208;T and BMI (continuous).HADS&#8208;T: Hospital Anxiety and Depression Scale &#8211; Total scale. BMI: Body mass index.<boxed-text position="anchor" content-type="graphic" id="prp21078-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PRP2-11-e01078-g003.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="prp21078-kwd-0001">antidepressants</kwd><kwd id="prp21078-kwd-0002">cardiovascular agents</kwd><kwd id="prp21078-kwd-0003">depression</kwd><kwd id="prp21078-kwd-0004">metformin</kwd><kwd id="prp21078-kwd-0005">neurosciences</kwd><kwd id="prp21078-kwd-0006">pharmacoepidemiology</kwd><kwd id="prp21078-kwd-0007">psychiatric disorders</kwd><kwd id="prp21078-kwd-0008">psychiatry</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Nord University
</institution><institution-id institution-id-type="doi">10.13039/100015995</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="12"/><word-count count="6810"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.7 mode:remove_FC converted:05.04.2023</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="PRP21078-cit-2001"><string-name name-style="western"><surname>Bojani&#263;</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bjerkeset</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>LJ</given-names></string-name>, et al. <article-title>Risk of antidepressant initiation among users of cardiovascular agents and metformin. Findings from the Tr&#248;ndelag Health Study (<styled-content style="fixed-case" toggle="no">HUNT</styled-content>) and Norwegian Prescription Database (<styled-content style="fixed-case" toggle="no">NorPD</styled-content>), Norway</article-title>. <source>Pharmacol Res Perspect</source>. <year>2023</year>;<volume>11</volume>:<elocation-id>e1078</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/prp2.1078</pub-id><pub-id pub-id-type="pmcid">PMC10073930</pub-id><pub-id pub-id-type="pmid">37016811</pub-id></mixed-citation>
</p></notes></front><body id="prp21078-body-0001"><def-list list-content="abbreviations" id="prp21078-lp-0001"><title>Abbreviations</title><def-item><term id="prp21078-li-0001">ACEI</term><def id="prp21078-li-0002"><p>angiotensin&#8208;converting enzyme inhibitors</p></def></def-item><def-item><term id="prp21078-li-0003">ARB</term><def id="prp21078-li-0004"><p>angiotensin II receptor blockers</p></def></def-item><def-item><term id="prp21078-li-0005">ASA</term><def id="prp21078-li-0006"><p>acetylsalicylic acid</p></def></def-item><def-item><term id="prp21078-li-0007">ATC</term><def id="prp21078-li-0008"><p>Anatomical Therapeutic Chemical classification</p></def></def-item><def-item><term id="prp21078-li-0009">BB</term><def id="prp21078-li-0010"><p>beta&#8208;blockers</p></def></def-item><def-item><term id="prp21078-li-0011">BMI</term><def id="prp21078-li-0012"><p>body mass index</p></def></def-item><def-item><term id="prp21078-li-0013">CCB</term><def id="prp21078-li-0014"><p>calcium channel blockers</p></def></def-item><def-item><term id="prp21078-li-0015">CI</term><def id="prp21078-li-0016"><p>confidence intervals</p></def></def-item><def-item><term id="prp21078-li-0017">CVD</term><def id="prp21078-li-0018"><p>cardiovascular diseases</p></def></def-item><def-item><term id="prp21078-li-0019">DM</term><def id="prp21078-li-0020"><p>diabetes mellitus</p></def></def-item><def-item><term id="prp21078-li-0021">EHR</term><def id="prp21078-li-0022"><p>electronic health records</p></def></def-item><def-item><term id="prp21078-li-0023">HADS</term><def id="prp21078-li-0024"><p>Hospital Anxiety and Depression Scale</p></def></def-item><def-item><term id="prp21078-li-0025">HPA</term><def id="prp21078-li-0026"><p>hypothalamic&#8211;pituitary&#8211;adrenal axis</p></def></def-item><def-item><term id="prp21078-li-0027">HRs</term><def id="prp21078-li-0028"><p>hazard ratios</p></def></def-item><def-item><term id="prp21078-li-0029">HUNT</term><def id="prp21078-li-0030"><p>Tr&#248;ndelag Health Study</p></def></def-item><def-item><term id="prp21078-li-0031">NorPD</term><def id="prp21078-li-0032"><p>Norwegian Prescription Database</p></def></def-item><def-item><term id="prp21078-li-0033">PH</term><def id="prp21078-li-0034"><p>proportional hazards</p></def></def-item><def-item><term id="prp21078-li-0035">RAS</term><def id="prp21078-li-0036"><p>renin&#8208;angiotensin system</p></def></def-item><def-item><term id="prp21078-li-0037">RCTs</term><def id="prp21078-li-0038"><p>randomized controlled trials</p></def></def-item></def-list><sec id="prp21078-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Depression is a common mental condition and is the leading cause of disability worldwide.<xref rid="prp21078-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Depression prevalence varies considerably across countries<xref rid="prp21078-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="prp21078-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="prp21078-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> and studies consistently report a higher prevalence of depression symptoms and disorders among those with cardiovascular diseases (CVDs) and diabetes mellitus (DM) than the general population.<xref rid="prp21078-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="prp21078-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="prp21078-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="prp21078-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="prp21078-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="prp21078-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Second&#8208;generation antidepressive agents targeting neurotransmitter systems are available; however, they can lead to adverse drug reactions or events,<xref rid="prp21078-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="prp21078-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="prp21078-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> have delayed initiation of efficacy,<xref rid="prp21078-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> and often have a poor (less than 50%) clinical response.<xref rid="prp21078-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> The discovery of new and improved antidepressants has not been fruitful in the past decades.<xref rid="prp21078-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> In contrast, finding new antidepressants among already available drugs with well&#8208;defined safety profiles (i.e., drug repurposing)<xref rid="prp21078-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> that affect biological pathways implicated in depression has aroused great interest.<xref rid="prp21078-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="prp21078-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="prp21078-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Moreover, the hypothalamic&#8211;pituitary&#8211;adrenal axis (HPA), renin&#8208;angiotensin system (RAS), immuno&#8208;inflammation, metabolic processes, and oxidative stress have been identified as shared pathophysiological mechanisms of CVDs, DM, and depression.<xref rid="prp21078-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="prp21078-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Cardiovascular<xref rid="prp21078-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="prp21078-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="prp21078-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="prp21078-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> and antidiabetic agents<xref rid="prp21078-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="prp21078-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="prp21078-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> targeting these mechanistic relationships have been associated with a reduced risk of depression. Although, it is still unclear which drugs can improve or prevent depression.<xref rid="prp21078-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="prp21078-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="prp21078-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="prp21078-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="prp21078-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="prp21078-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p><p>Evidence investigating the association between cardiovascular agents and metformin on depression risk among the general population and those with CVDs or DM has been mixed. Among the total Danish population (over 3.7 million), depression risk was reduced among users of angiotensin II receptor blockers (ARBs) or angiotensin&#8208;converting enzyme inhibitors (ACEI), calcium channel blockers (CCB) and beta&#8208;blockers (BB), low&#8208;dose acetylsalicylic acid (ASA), and statins.<xref rid="prp21078-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> In contrast, among 1.8 million Scottish hypertensive patients, mono&#8208; or polytherapy with ACEI, ARBs, CCB, and BB was associated with an increased risk of new&#8208;onset or recurrent depression compared to no use of these drugs.<xref rid="prp21078-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> However, a meta&#8208;analysis and systematic review of clinical and population&#8208;based studies suggested that statins may improve depression.<xref rid="prp21078-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="prp21078-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="prp21078-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> In contrast, the benefits of ARBs, ACEI, ASA, and CCB on depression were not confirmed.<xref rid="prp21078-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="prp21078-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> So far, the associations between diuretics and improved mood disorders, including depression, have been limited.<xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="prp21078-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="prp21078-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Furthermore, case&#8211;control study of type 2 DM patients found a lower risk of depression among patients using metformin (<italic toggle="yes">N</italic>&#160;=&#160;110) compared to a non&#8208;treated control group,<xref rid="prp21078-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> whereas a meta&#8208;analysis of the small number of pilot randomized controlled trials (RCTs) yielded no evidence of this drug's clinical benefits for depression.<xref rid="prp21078-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p><p>Electronic health records (EHRs) (e.g., hospital data and prescription records) combined with health surveys are a novel source for identifying potential drug repurposing signals.<xref rid="prp21078-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> From this perspective, observational EHRs&#8208;based studies can provide valuable &#8220;real&#8208;world evidence&#8221; of associations between drug use and health outcomes.<xref rid="prp21078-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> In Norway, we can combine extensive data from the national prescription registry with health surveys. This study aimed to assess cardiovascular agents and metformin as potential risk or protective factors for the initiation of antidepressant therapy, used as a proxy for the possible diagnosis of depression. Among over 20&#8201;000 adults, we wanted to examine whether and to what extent initiating therapy of cardiovascular agents or metformin is associated with risk of antidepressant initiation during a ten&#8208;year follow&#8208;up period.</p></sec><sec sec-type="methods" id="prp21078-sec-0002"><label>2</label><title>METHODS</title><sec id="prp21078-sec-0003"><label>2.1</label><title>Data sources</title><p>We used data from the Tr&#248;ndelag Health Study (HUNT), Norway, linked to the Norwegian Prescription Database (NorPD). The HUNT Study is a population&#8208;based health study that comprises adult residents (&#8805;20&#8201;years old) of Tr&#248;ndelag County (of around 190&#8201;000 inhabitants) in Norway. Four surveys have been conducted so far: the HUNT1 (1984&#8211;86), the HUNT2 (1995&#8211;97), the HUNT3 (2006&#8211;08), and the HUNT4 (2017&#8211;19), with a response rate of 77&#8201;212 (89.4%), 65&#8201;237 (69.5%), 50&#8201;807 (54.1%), and 56&#8201;078 (54%), respectively. The HUNT population is considered representative of general Norwegian adults.<xref rid="prp21078-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> The questions in HUNT include items on health conditions, including self&#8208;reported psychological symptoms, lifestyle, and sociodemographic characteristics. Details about the study are described elsewhere.<xref rid="prp21078-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>
</p><p>NorPD contains electronic records of all prescription drugs dispensed by pharmacies in Norway since 2004 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fhi.no/en/hn/health-registries/norpd/" ext-link-type="uri">https://www.fhi.no/en/hn/health&#8208;registries/norpd/</ext-link>). Drugs are classified according to the World Health Organization Anatomical Therapeutic Chemical classification (ATC) system.<xref rid="prp21078-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> This study included information from NorPD on the participant (i.e., sex and birth year), dispensed prescriptions (i.e., monthly and yearly dispensing) and drugs (ATC code).</p></sec><sec id="prp21078-sec-0004"><label>2.2</label><title>Study population</title><p>This study included HUNT3 participants whose drug prescription records were collected from NorPD through a unique personal number. Based on available NorPD data from January 1st 2006, to the date of participation in HUNT3 (from 3 October 2006 to 25 June 2008), we identified and excluded individuals who received a prescription of one or more cardiovascular agents (i.e., ACEI, ARBs, ASA, BB, CCB, diuretics, or statins), metformin, or antidepressants. The date of drug dispensation was defined by month and year. Individuals with no dispensed prescriptions of drugs included in this study during 6&#8201;months before their participation date in HUNT3 (baseline) were eligible, from which we excluded participants aged &lt;40 or&#8201;&gt;&#8201;70&#8201;years at baseline (<italic toggle="yes">n</italic>&#160;=&#160;12&#8201;580). Participants aged 40&#8211;70&#8201;years were assumed to be most likely (i.e., at risk) to experience the exposure and outcome and were therefore included in the analysis. Due to a high number of competing risk factors (i.e., other comorbidities, polypharmacy, and death) that may interfere with the outcome (initiation of antidepressants), participants over 70&#8201;years of age were not analyzed. The remaining 20&#8201;227 individuals were included in the study population. Figure&#160;<xref rid="prp21078-fig-0001" ref-type="fig">1</xref> shows the flow chart of the study participant selection process. The study population was followed for 10&#8201;years from enrolment in the HUNT3 study or up to their first dispensed antidepressant prescription, whichever occurred first.</p><fig position="float" fig-type="FIGURE" id="prp21078-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Flow chart showing selection process of study population. *Prescriptions of cardiovascular, antidiabetic, and antidepressant agents.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PRP2-11-e01078-g001.jpg"/></fig></sec><sec id="prp21078-sec-0005"><label>2.3</label><title>Exposure</title><p>The exposure was defined as the use of one (monotherapy) or more (polytherapy) cardiovascular agents or metformin, based on the available data on the first dispensed prescription (defined by month and year). Dispensed prescriptions have been previously confirmed as a reliable measurement of drug use.<xref rid="prp21078-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Selection of drug classes for the analysis was based on their associations with depression suggested by the literature<xref rid="prp21078-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="prp21078-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="prp21078-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="prp21078-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="prp21078-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="prp21078-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> and the number of users in our data that provided sufficient statistical power. Diuretics as a drug subgroup (ATC C03) were included as a negative control because these drugs have not been associated with mood disorders.<xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="prp21078-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The following cardiovascular agents and metformin, defined according to ATC codes, were analyzed: ACEI (C09A), ARBs (CO9C), ASA (B01A C06), BB (C07), CCB (C08), diuretics (C03), statins, that is, HMG&#8208;CoA&#8208;reductase inhibitors (C10A A), and metformin (A10B A02). The exposure status of study participants was defined by their first drug dispensation after the start of follow&#8208;up: (1) <italic toggle="yes">monotherapy</italic>&#8208; for participants who received a single drug class by their first dispensation (2) <italic toggle="yes">polytherapy</italic>&#8208; for participants who received more than one drug class by their first dispensation and (3) <italic toggle="yes">no&#8208;drug use</italic> (<italic toggle="yes">reference</italic>)&#8208; for participants with no dispensed prescriptions for metformin or any cardiovascular agents included in this study.</p></sec><sec id="prp21078-sec-0006"><label>2.4</label><title>Outcome</title><p>The outcome was the initiation of antidepressant therapy during the study period. The NorPD database provides diagnostic information from the ICD&#8208;10 or ICPC&#8208;2 for prescriptions only after 2008. Therefore, only antidepressant prescriptions were used as the outcome and proxy for possible depression (and/or anxiety) at the diagnostic level in this study. We used the first dispensation of an antidepressant agent to identify antidepressant therapy initiation. All antidepressants as a drug subgroup (ATC code NO6) were included in the analysis. Among them, the following antidepressant agents with ATC codes were the ones with highest number of users among the study population: non&#8208;selective monoamine reuptake inhibitors (N06A A), selective serotonin reuptake inhibitors (N06A B), monoamine oxidase A inhibitors (N06A G02), and other antidepressants (N06A X).</p></sec><sec id="prp21078-sec-0007"><label>2.5</label><title>Other covariates</title><p>Sociodemographic characteristics included: sex and age (mean and age groups 40&#8211;54 and 55&#8211;70&#8201;years). Lifestyle measurements included questions on current smoking (yes/no), physical activity per week (inactive versus active), and monthly alcohol consumption (no or low versus moderate to frequent). Physical activity was defined as light if it did not involve sweating or breathlessness. The participants were categorized as active (one time per week of hard/light physical activity) or inactive (no physical activity or less than one time per week). Alcohol consumption never or&#8201;&#8804;&#8201;one time per week was defined as no or low drinking, while drinking from two to three times or&#8201;&#8805;&#8201;four times per week was defined as moderate to frequent drinking. Chronic diseases (yes/no) were determined with the question: &#8220;Do you suffer from a long&#8208;lasting (at least one year) illness or injury of a physical or psychological nature that impairs your functioning in your daily life?&#8221;. The Hospital Anxiety and Depression Scale (HADS) was used to assess psychological symptoms of anxiety (HADS&#8208;A subscale) and depression (HADS&#8208;D) during the past week and describe symptom change (HADS&#8208;T) from HUNT2 to HUNT3. Questions on HADS have a 4&#8208;point Likert scale response option from 0 (no symptoms) to 3 (highest symptom level). We used total scores (HADS&#8208;T) by summing up valid HADS&#8208;A and HADS&#8208;D, defined as a response on five or more items. The missing response among participants who filled in 5 or 6 items was replaced with the sum of completed items multiplied by 7/5 or 6/5, respectively. The HADS&#8208;D subscale is a reliable instrument for detecting symptoms of depression (with or without anxiety) and describing symptom severity among both general and clinical populations.<xref rid="prp21078-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="prp21078-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> Clinical measurements included height (m) and weight (kg) used to determine body mass index (BMI; kg/m<sup>2</sup>).</p></sec><sec id="prp21078-sec-0008"><label>2.6</label><title>Data analysis</title><p>We used Cox proportional hazards (PH) models to examine associations between cardiovascular agents and metformin and the risk for antidepressant therapy initiation. Estimates were presented as hazard ratios (HRs) with corresponding 95% confidence intervals (CI). The preliminary test of proportionality of hazard, using log&#8211;log curves<xref rid="prp21078-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> and Schoenfeld residuals,<xref rid="prp21078-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> suggested that the PH assumption may be violated. We addressed this issue by delaying the start of follow&#8208;up for three and six months and one year after baseline. Our models improved but yielded essentially the same results, indicating that possible non&#8208;proportionality in our data would not substantially influence the interpretation of our results. The follow&#8208;up time started in HUNT3 (baseline) for all study participants. To prevent introduction of immortal time bias to analysis, the follow&#8208;up time was restarted (split) at the first dispensation date (month/year) of cardiovascular agents or metformin (exposures). Participants defined as no&#8208;drug users (reference) at baseline were first followed to their first drug prescription; then their unexposed person time ended. Thereafter, they changed exposure status (to either mono&#8208; or polytherapy) and were followed to first antidepressant prescription or end of follow&#8208;up. Thus, the follow&#8208;up period included both pre&#8208; and post&#8208;exposure period during which participants could experience the outcome (i.e., they were not immortal).</p><p>Models were first adjusted for sex and age as a time&#8208;varying covariate (Model 1), thereby HADS&#8208;T and BMI at baseline as continuous variables (Model 2). The point estimates (Models 1) remained fairly robust after the adjustment (Models 2). Further adjustment for lifestyle and chronic diseases yielded minimal changes to the results, and these variables were not included in the main analysis (Models 1 and 2).</p></sec></sec><sec sec-type="results" id="prp21078-sec-0009"><label>3</label><title>RESULTS</title><p>The baseline characteristics of study participants according to the use of cardiovascular agents and metformin, monotherapy (mono), or polytherapy (poly) during the follow&#8208;up are shown in Table&#160;<xref rid="prp21078-tbl-0001" ref-type="table">1</xref>. The number of drug users (Table&#160;<xref rid="prp21078-tbl-0001" ref-type="table">1</xref>) is cumulative for the entire follow&#8208;up period. Users of various drug classes differed by sex, except for diuretics polytherapy, where there was an equal sex distribution. Men were more likely to be users of metformin and most cardiovascular agents, while BB, statin, and diuretic monotherapy users were more likely to be women. The mean age of the study participants ranged from 51&#8211;58&#8201;years, with most participants being non (current) smokers, physically active, and no or low alcohol consumers. Compared to reference, mono and polytherapy users of various drug classes showed marginal differences in self&#8208;reported chronic diseases, BMI (mean range 26.9&#8211;31.0&#160;kg/m<sup>2</sup>), and HADS&#8208;T score change from HUNT2 to HUNT3 (7.0 to 6.6). The initiation of antidepressant use was more common among the reference group than among participants using mono or polytherapy for all drug classes.</p><table-wrap position="float" id="prp21078-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Baseline characteristics of study participants according to the use of cardiovascular agents or metformin during a 10&#8208;year follow&#8208;up. The number of drug users (mono/polytherapy) is cumulative for the entire follow&#8208;up period.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1"/><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic> total</th><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Reference</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">ACEI</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">ARBs</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">ASA</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">BB</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variables <italic toggle="yes">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">20&#8201;227</th><th align="left" valign="bottom" rowspan="1" colspan="1">11&#8201;758</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mono <italic toggle="yes">N</italic>&#160;=&#160;397</th><th align="left" valign="bottom" rowspan="1" colspan="1">Poly <italic toggle="yes">N</italic>&#160;=&#160;267</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mono <italic toggle="yes">N</italic>&#160;=&#160;1181</th><th align="left" valign="bottom" rowspan="1" colspan="1">Poly <italic toggle="yes">N</italic>&#160;=&#160;217</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mono <italic toggle="yes">N</italic>&#160;=&#160;655</th><th align="left" valign="bottom" rowspan="1" colspan="1">Poly <italic toggle="yes">N</italic>&#160;=&#160;1054</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mono <italic toggle="yes">N</italic>&#160;=&#160;667</th><th align="left" valign="bottom" rowspan="1" colspan="1">Poly <italic toggle="yes">N</italic>&#160;=&#160;579</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="11" valign="top" rowspan="1">Sex</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Women</td><td align="left" valign="top" rowspan="1" colspan="1">10&#8201;544</td><td align="left" valign="top" rowspan="1" colspan="1">6462 (55.0)</td><td align="left" valign="top" rowspan="1" colspan="1">172 (43.3)</td><td align="left" valign="top" rowspan="1" colspan="1">82 (30.7)</td><td align="left" valign="top" rowspan="1" colspan="1">524 (44.4)</td><td align="left" valign="top" rowspan="1" colspan="1">87 (40.0)</td><td align="left" valign="top" rowspan="1" colspan="1">316 (48.2)</td><td align="left" valign="top" rowspan="1" colspan="1">357 (33.9)</td><td align="left" valign="top" rowspan="1" colspan="1">361 (54.1)</td><td align="left" valign="top" rowspan="1" colspan="1">162 (28.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Men</td><td align="left" valign="top" rowspan="1" colspan="1">9683</td><td align="left" valign="top" rowspan="1" colspan="1">5296 (45.0)</td><td align="left" valign="top" rowspan="1" colspan="1">225 (56.7)</td><td align="left" valign="top" rowspan="1" colspan="1">185 (69.3)</td><td align="left" valign="top" rowspan="1" colspan="1">657 (55.6)</td><td align="left" valign="top" rowspan="1" colspan="1">130 (60.0)</td><td align="left" valign="top" rowspan="1" colspan="1">339 (51.8)</td><td align="left" valign="top" rowspan="1" colspan="1">697 (66.1)</td><td align="left" valign="top" rowspan="1" colspan="1">306 (45.9)</td><td align="left" valign="top" rowspan="1" colspan="1">417 (72.0)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Age (years)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)<xref rid="prp21078-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">51.2 (7.7)</td><td align="left" valign="top" rowspan="1" colspan="1">54.7 (7.9)</td><td align="left" valign="top" rowspan="1" colspan="1">57.1 (7.8)</td><td align="left" valign="top" rowspan="1" colspan="1">53.8 (8.0)</td><td align="left" valign="top" rowspan="1" colspan="1">55.6 (7.6)</td><td align="left" valign="top" rowspan="1" colspan="1">57.3 (7.9)</td><td align="left" valign="top" rowspan="1" colspan="1">57.5 (7.2)</td><td align="left" valign="top" rowspan="1" colspan="1">54.8 (8.2)</td><td align="left" valign="top" rowspan="1" colspan="1">57.5 (7.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">40&#8211;54</td><td align="left" valign="top" rowspan="1" colspan="1">12&#8201;115</td><td align="left" valign="top" rowspan="1" colspan="1">8093 (68.8)</td><td align="left" valign="top" rowspan="1" colspan="1">199 (50.1)</td><td align="left" valign="top" rowspan="1" colspan="1">103 (38.6)</td><td align="left" valign="top" rowspan="1" colspan="1">655 (55.5)</td><td align="left" valign="top" rowspan="1" colspan="1">95 (43.8)</td><td align="left" valign="top" rowspan="1" colspan="1">249 (38.0)</td><td align="left" valign="top" rowspan="1" colspan="1">363 (34.4)</td><td align="left" valign="top" rowspan="1" colspan="1">337 (50.5)</td><td align="left" valign="top" rowspan="1" colspan="1">201 (34.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">55&#8211;70</td><td align="left" valign="top" rowspan="1" colspan="1">8112</td><td align="left" valign="top" rowspan="1" colspan="1">3665 (31.2)</td><td align="left" valign="top" rowspan="1" colspan="1">198 (49.1)</td><td align="left" valign="top" rowspan="1" colspan="1">164 (61.4)</td><td align="left" valign="top" rowspan="1" colspan="1">526 (44.5)</td><td align="left" valign="top" rowspan="1" colspan="1">122 (56.2)</td><td align="left" valign="top" rowspan="1" colspan="1">406 (62.0)</td><td align="left" valign="top" rowspan="1" colspan="1">691 (65.6)</td><td align="left" valign="top" rowspan="1" colspan="1">330 (49.5)</td><td align="left" valign="top" rowspan="1" colspan="1">378 (65.3)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Chronic diseases</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">6205</td><td align="left" valign="top" rowspan="1" colspan="1">3669 (31.2)</td><td align="left" valign="top" rowspan="1" colspan="1">120 (30.2)</td><td align="left" valign="top" rowspan="1" colspan="1">81 (30.4)</td><td align="left" valign="top" rowspan="1" colspan="1">372 (31.5)</td><td align="left" valign="top" rowspan="1" colspan="1">75 (34.6)</td><td align="left" valign="top" rowspan="1" colspan="1">199 (30.4)</td><td align="left" valign="top" rowspan="1" colspan="1">312 (29.6)</td><td align="left" valign="top" rowspan="1" colspan="1">195 (29.3)</td><td align="left" valign="top" rowspan="1" colspan="1">170 (29.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">5310</td><td align="left" valign="top" rowspan="1" colspan="1">3103 (26.4)</td><td align="left" valign="top" rowspan="1" colspan="1">97 (24.4)</td><td align="left" valign="top" rowspan="1" colspan="1">69 (25.8)</td><td align="left" valign="top" rowspan="1" colspan="1">302 (25.6)</td><td align="left" valign="top" rowspan="1" colspan="1">63 (29.0)</td><td align="left" valign="top" rowspan="1" colspan="1">187 (28.5)</td><td align="left" valign="top" rowspan="1" colspan="1">304 (28.8)</td><td align="left" valign="top" rowspan="1" colspan="1">175 (26.2)</td><td align="left" valign="top" rowspan="1" colspan="1">156 (26.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">8712</td><td align="left" valign="top" rowspan="1" colspan="1">4986 (42.4)</td><td align="left" valign="top" rowspan="1" colspan="1">180 (45.4)</td><td align="left" valign="top" rowspan="1" colspan="1">117 (43.8)</td><td align="left" valign="top" rowspan="1" colspan="1">507 (42.9)</td><td align="left" valign="top" rowspan="1" colspan="1">79 (36.4)</td><td align="left" valign="top" rowspan="1" colspan="1">269 (41.1)</td><td align="left" valign="top" rowspan="1" colspan="1">438 (41.6)</td><td align="left" valign="top" rowspan="1" colspan="1">297 (44.5)</td><td align="left" valign="top" rowspan="1" colspan="1">253 (43.7)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Current smoking</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">14&#8201;557</td><td align="left" valign="top" rowspan="1" colspan="1">8592 (73.1)</td><td align="left" valign="top" rowspan="1" colspan="1">289 (72.8)</td><td align="left" valign="top" rowspan="1" colspan="1">189 (70.8)</td><td align="left" valign="top" rowspan="1" colspan="1">833 (70.5)</td><td align="left" valign="top" rowspan="1" colspan="1">165 (76.0)</td><td align="left" valign="top" rowspan="1" colspan="1">478 (73.0)</td><td align="left" valign="top" rowspan="1" colspan="1">761 (72.2)</td><td align="left" valign="top" rowspan="1" colspan="1">475 (71.2)</td><td align="left" valign="top" rowspan="1" colspan="1">412 (71.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">5219</td><td align="left" valign="top" rowspan="1" colspan="1">2918 (24.8)</td><td align="left" valign="top" rowspan="1" colspan="1">101 (25.4)</td><td align="left" valign="top" rowspan="1" colspan="1">74 (27.2)</td><td align="left" valign="top" rowspan="1" colspan="1">326 (27.6)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (21.6)</td><td align="left" valign="top" rowspan="1" colspan="1">163 (24.9)</td><td align="left" valign="top" rowspan="1" colspan="1">270 (25.6)</td><td align="left" valign="top" rowspan="1" colspan="1">175 (26.3)</td><td align="left" valign="top" rowspan="1" colspan="1">154 (26.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">451</td><td align="left" valign="top" rowspan="1" colspan="1">248 (2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (2.2)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Physical activity</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Inactive<xref rid="prp21078-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">809</td><td align="left" valign="top" rowspan="1" colspan="1">391 (3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">48 (4.1)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (4.1)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (4.7)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (5.8)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (5.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Active<xref rid="prp21078-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">19&#8201;351</td><td align="left" valign="top" rowspan="1" colspan="1">11&#8201;330 (96.4)</td><td align="left" valign="top" rowspan="1" colspan="1">385 (97.0)</td><td align="left" valign="top" rowspan="1" colspan="1">254 (95.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1126 (95.3)</td><td align="left" valign="top" rowspan="1" colspan="1">208 (95.9)</td><td align="left" valign="top" rowspan="1" colspan="1">622 (95.0)</td><td align="left" valign="top" rowspan="1" colspan="1">990 (93.9)</td><td align="left" valign="top" rowspan="1" colspan="1">628 (94.2)</td><td align="left" valign="top" rowspan="1" colspan="1">543 (93.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">67</td><td align="left" valign="top" rowspan="1" colspan="1">37 (0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (0.5)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Alcohol consumption</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No or low<xref rid="prp21078-note-0006" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">10&#8201;839</td><td align="left" valign="top" rowspan="1" colspan="1">6263 (53.3)</td><td align="left" valign="top" rowspan="1" colspan="1">217 (54.6)</td><td align="left" valign="top" rowspan="1" colspan="1">144 (54.0)</td><td align="left" valign="top" rowspan="1" colspan="1">623 (52.8)</td><td align="left" valign="top" rowspan="1" colspan="1">116 (53.6)</td><td align="left" valign="top" rowspan="1" colspan="1">355 (54.2)</td><td align="left" valign="top" rowspan="1" colspan="1">572 (54.3)</td><td align="left" valign="top" rowspan="1" colspan="1">338 (50.7)</td><td align="left" valign="top" rowspan="1" colspan="1">326 (56.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Moderate to frequent<xref rid="prp21078-note-0007" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">9069</td><td align="left" valign="top" rowspan="1" colspan="1">5313 (45.2)</td><td align="left" valign="top" rowspan="1" colspan="1">171 (43.1)</td><td align="left" valign="top" rowspan="1" colspan="1">120 (44.9)</td><td align="left" valign="top" rowspan="1" colspan="1">544 (46.1)</td><td align="left" valign="top" rowspan="1" colspan="1">99 (45.5)</td><td align="left" valign="top" rowspan="1" colspan="1">292 (44.6)</td><td align="left" valign="top" rowspan="1" colspan="1">465 (44.1)</td><td align="left" valign="top" rowspan="1" colspan="1">318 (47.7)</td><td align="left" valign="top" rowspan="1" colspan="1">241 (41.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">319</td><td align="left" valign="top" rowspan="1" colspan="1">182 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.9)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">12(2.1)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">BMI</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">26.2 (3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">28.3 (4.1)</td><td align="left" valign="top" rowspan="1" colspan="1">28.1 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">28.3 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">28.1 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">26.7 (3.8)</td><td align="left" valign="top" rowspan="1" colspan="1">27.2 (3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">26.9 (3.8)</td><td align="left" valign="top" rowspan="1" colspan="1">27.6 (3.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">90</td><td align="left" valign="top" rowspan="1" colspan="1">47 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (0.2)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">HADS&#8208;T (HUNT2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Valid<sup>f</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">16&#8201;308</td><td align="left" valign="top" rowspan="1" colspan="1">9295 (79.1)</td><td align="left" valign="top" rowspan="1" colspan="1">318 (80.1)</td><td align="left" valign="top" rowspan="1" colspan="1">198 (74.2)</td><td align="left" valign="top" rowspan="1" colspan="1">900 (76.1)</td><td align="left" valign="top" rowspan="1" colspan="1">162 (74.7)</td><td align="left" valign="top" rowspan="1" colspan="1">559 (85.3)</td><td align="left" valign="top" rowspan="1" colspan="1">819 (77.7)</td><td align="left" valign="top" rowspan="1" colspan="1">538 (80.8)</td><td align="left" valign="top" rowspan="1" colspan="1">457 (78.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">6.9 (5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">7.0 (4.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7.14 (5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">7.2 (5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">6.6 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">7.3 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">7.4 (5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">7.5 (5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">7.3 (5.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">3919</td><td align="left" valign="top" rowspan="1" colspan="1">2463 (15.8)</td><td align="left" valign="top" rowspan="1" colspan="1">79 (19.9)</td><td align="left" valign="top" rowspan="1" colspan="1">69 (25.8)</td><td align="left" valign="top" rowspan="1" colspan="1">281 (23.8)</td><td align="left" valign="top" rowspan="1" colspan="1">55 (25.3)</td><td align="left" valign="top" rowspan="1" colspan="1">96 (14.7)</td><td align="left" valign="top" rowspan="1" colspan="1">235 (22.3)</td><td align="left" valign="top" rowspan="1" colspan="1">129 (19.2)</td><td align="left" valign="top" rowspan="1" colspan="1">122 (21.1)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">HADS&#8208;T (HUNT3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Valid<xref rid="prp21078-note-0008" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">16&#8201;542</td><td align="left" valign="top" rowspan="1" colspan="1">9577 (81.5)</td><td align="left" valign="top" rowspan="1" colspan="1">320 (80.6)</td><td align="left" valign="top" rowspan="1" colspan="1">207 (77.5)</td><td align="left" valign="top" rowspan="1" colspan="1">952 (80.6)</td><td align="left" valign="top" rowspan="1" colspan="1">169 (77.9)</td><td align="left" valign="top" rowspan="1" colspan="1">556 (84.9)</td><td align="left" valign="top" rowspan="1" colspan="1">834 (79.1)</td><td align="left" valign="top" rowspan="1" colspan="1">550 (82.5)</td><td align="left" valign="top" rowspan="1" colspan="1">453 (78.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">6.63 (5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">6.1 (4.4)</td><td align="left" valign="top" rowspan="1" colspan="1">6.6 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6.6 (4.7)</td><td align="left" valign="top" rowspan="1" colspan="1">6.2 (4.7)</td><td align="left" valign="top" rowspan="1" colspan="1">6.8 (4.9)</td><td align="left" valign="top" rowspan="1" colspan="1">6.7 (5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">6.9 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">6.8 (5.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">3685</td><td align="left" valign="top" rowspan="1" colspan="1">2181 (13.4)</td><td align="left" valign="top" rowspan="1" colspan="1">77 (19.4)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (22.5)</td><td align="left" valign="top" rowspan="1" colspan="1">229 (19.4)</td><td align="left" valign="top" rowspan="1" colspan="1">48 (22.1)</td><td align="left" valign="top" rowspan="1" colspan="1">99 (15.1)</td><td align="left" valign="top" rowspan="1" colspan="1">220 (20.9)</td><td align="left" valign="top" rowspan="1" colspan="1">117 (17.5)</td><td align="left" valign="top" rowspan="1" colspan="1">126 (21.8)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Initiation of antidepressant use<xref rid="prp21078-note-0009" ref-type="table-fn">
<sup>g</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">3194</td><td align="left" valign="top" rowspan="1" colspan="1">2275 (19.3)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (9.1)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (12.7)</td><td align="left" valign="top" rowspan="1" colspan="1">101 (8.6)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (10.1)</td><td align="left" valign="top" rowspan="1" colspan="1">109 (16.6)</td><td align="left" valign="top" rowspan="1" colspan="1">106 (10.1)</td><td align="left" valign="top" rowspan="1" colspan="1">88 (13.2)</td><td align="left" valign="top" rowspan="1" colspan="1">58 (10.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">17&#8201;033</td><td align="left" valign="top" rowspan="1" colspan="1">9483 (80.7)</td><td align="left" valign="top" rowspan="1" colspan="1">361 (90.9)</td><td align="left" valign="top" rowspan="1" colspan="1">233 (87.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1080 (91.4)</td><td align="left" valign="top" rowspan="1" colspan="1">195 (89.9)</td><td align="left" valign="top" rowspan="1" colspan="1">546 (83.4)</td><td align="left" valign="top" rowspan="1" colspan="1">948 (89.9)</td><td align="left" valign="top" rowspan="1" colspan="1">579 (86.8)</td><td align="left" valign="top" rowspan="1" colspan="1">521 (90.0)</td></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1"/><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">N total</th><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Reference</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">CCB</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Diuretics</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Statins</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Metformin</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variables <italic toggle="yes">n</italic> (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">20&#8201;227</th><th align="left" valign="bottom" rowspan="1" colspan="1">11&#8201;758</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mono <italic toggle="yes">N</italic>&#160;=&#160;694</th><th align="left" valign="bottom" rowspan="1" colspan="1">Poly <italic toggle="yes">N</italic>&#160;=&#160;204</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mono <italic toggle="yes">N</italic>&#160;=&#160;790</th><th align="left" valign="bottom" rowspan="1" colspan="1">Poly <italic toggle="yes">N</italic>&#160;=&#160;158</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mono <italic toggle="yes">N</italic>&#160;=&#160;1132</th><th align="left" valign="bottom" rowspan="1" colspan="1">Poly <italic toggle="yes">N</italic>&#160;=&#160;1057</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mono <italic toggle="yes">N</italic>&#160;=&#160;237</th><th align="left" valign="bottom" rowspan="1" colspan="1">Poly <italic toggle="yes">N</italic>&#160;=&#160;68</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="11" valign="top" rowspan="1">Sex</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Women</td><td align="left" valign="top" rowspan="1" colspan="1">10&#8201;544</td><td align="left" valign="top" rowspan="1" colspan="1">6462 (55.0)</td><td align="left" valign="top" rowspan="1" colspan="1">331 (47.7)</td><td align="left" valign="top" rowspan="1" colspan="1">86 (42.2)</td><td align="left" valign="top" rowspan="1" colspan="1">481 (60.9)</td><td align="left" valign="top" rowspan="1" colspan="1">79 (50.0)</td><td align="left" valign="top" rowspan="1" colspan="1">689 (60.9)</td><td align="left" valign="top" rowspan="1" colspan="1">371 (35.1)</td><td align="left" valign="top" rowspan="1" colspan="1">83 (37.6)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (32.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Men</td><td align="left" valign="top" rowspan="1" colspan="1">9683</td><td align="left" valign="top" rowspan="1" colspan="1">5296 (45.0)</td><td align="left" valign="top" rowspan="1" colspan="1">363 (52.3)</td><td align="left" valign="top" rowspan="1" colspan="1">118 (57.8)</td><td align="left" valign="top" rowspan="1" colspan="1">309 (39.1)</td><td align="left" valign="top" rowspan="1" colspan="1">79 (50.0)</td><td align="left" valign="top" rowspan="1" colspan="1">443 (39.1)</td><td align="left" valign="top" rowspan="1" colspan="1">686 (64.9)</td><td align="left" valign="top" rowspan="1" colspan="1">154 (62.4)</td><td align="left" valign="top" rowspan="1" colspan="1">46 (67.6)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Age (years)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)<xref rid="prp21078-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">51.2 (7.7)</td><td align="left" valign="top" rowspan="1" colspan="1">55.4 (7.7)</td><td align="left" valign="top" rowspan="1" colspan="1">55.5 (8.0)</td><td align="left" valign="top" rowspan="1" colspan="1">56.0 (8.0)</td><td align="left" valign="top" rowspan="1" colspan="1">58.1 (7.7)</td><td align="left" valign="top" rowspan="1" colspan="1">55.0 (7.3)</td><td align="left" valign="top" rowspan="1" colspan="1">57.1 (7.4)</td><td align="left" valign="top" rowspan="1" colspan="1">55.0 (7.7)</td><td align="left" valign="top" rowspan="1" colspan="1">53.4 (8.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">40&#8211;54</td><td align="left" valign="top" rowspan="1" colspan="1">12&#8201;115</td><td align="left" valign="top" rowspan="1" colspan="1">8093 (68.8)</td><td align="left" valign="top" rowspan="1" colspan="1">312 (45.0)</td><td align="left" valign="top" rowspan="1" colspan="1">91 (44.6)</td><td align="left" valign="top" rowspan="1" colspan="1">358 (45.3)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (28.5)</td><td align="left" valign="top" rowspan="1" colspan="1">548 (48.4)</td><td align="left" valign="top" rowspan="1" colspan="1">384 (33.3)</td><td align="left" valign="top" rowspan="1" colspan="1">114 (48.1)</td><td align="left" valign="top" rowspan="1" colspan="1">38 (55.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">55&#8211;70</td><td align="left" valign="top" rowspan="1" colspan="1">8112</td><td align="left" valign="top" rowspan="1" colspan="1">3665 (31.2)</td><td align="left" valign="top" rowspan="1" colspan="1">382 (55.0)</td><td align="left" valign="top" rowspan="1" colspan="1">113 (55.4)</td><td align="left" valign="top" rowspan="1" colspan="1">432 (54.7)</td><td align="left" valign="top" rowspan="1" colspan="1">113 (71.5)</td><td align="left" valign="top" rowspan="1" colspan="1">584 (51.6)</td><td align="left" valign="top" rowspan="1" colspan="1">673 (66.7)</td><td align="left" valign="top" rowspan="1" colspan="1">123 (51.9)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (44.1)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Chronic diseases</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">6205</td><td align="left" valign="top" rowspan="1" colspan="1">3669 (31.2)</td><td align="left" valign="top" rowspan="1" colspan="1">202 (29.1)</td><td align="left" valign="top" rowspan="1" colspan="1">57 (27.9)</td><td align="left" valign="top" rowspan="1" colspan="1">236 (29.9)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (28.5)</td><td align="left" valign="top" rowspan="1" colspan="1">314 (27.7)</td><td align="left" valign="top" rowspan="1" colspan="1">324 (30.7)</td><td align="left" valign="top" rowspan="1" colspan="1">79 (33.3)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (23.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">5310</td><td align="left" valign="top" rowspan="1" colspan="1">3103 (26.4)</td><td align="left" valign="top" rowspan="1" colspan="1">182 (26.2)</td><td align="left" valign="top" rowspan="1" colspan="1">64 (31.4)</td><td align="left" valign="top" rowspan="1" colspan="1">209 (26.5)</td><td align="left" valign="top" rowspan="1" colspan="1">44 (27.8)</td><td align="left" valign="top" rowspan="1" colspan="1">306 (27.0)</td><td align="left" valign="top" rowspan="1" colspan="1">307 (29.0)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (25.3)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (26.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">8712</td><td align="left" valign="top" rowspan="1" colspan="1">4986 (42.4)</td><td align="left" valign="top" rowspan="1" colspan="1">310 (44.7)</td><td align="left" valign="top" rowspan="1" colspan="1">83 (40.7)</td><td align="left" valign="top" rowspan="1" colspan="1">345 (43.6)</td><td align="left" valign="top" rowspan="1" colspan="1">69 (43.7)</td><td align="left" valign="top" rowspan="1" colspan="1">512 (45.3)</td><td align="left" valign="top" rowspan="1" colspan="1">426 (40.3)</td><td align="left" valign="top" rowspan="1" colspan="1">98 (41.4)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (50.0)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Current smoking</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">14&#8201;557</td><td align="left" valign="top" rowspan="1" colspan="1">8592 (73.1)</td><td align="left" valign="top" rowspan="1" colspan="1">483 (69.6)</td><td align="left" valign="top" rowspan="1" colspan="1">153 (75.0)</td><td align="left" valign="top" rowspan="1" colspan="1">560 (70.9)</td><td align="left" valign="top" rowspan="1" colspan="1">113 (71.5)</td><td align="left" valign="top" rowspan="1" colspan="1">816 (71.9)</td><td align="left" valign="top" rowspan="1" colspan="1">769 (72.8)</td><td align="left" valign="top" rowspan="1" colspan="1">169 (71.3)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (69.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">5219</td><td align="left" valign="top" rowspan="1" colspan="1">2918 (24.8)</td><td align="left" valign="top" rowspan="1" colspan="1">198 (28.5)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (23.0)</td><td align="left" valign="top" rowspan="1" colspan="1">211 (26.7)</td><td align="left" valign="top" rowspan="1" colspan="1">40 (25.3)</td><td align="left" valign="top" rowspan="1" colspan="1">292 (25.8)</td><td align="left" valign="top" rowspan="1" colspan="1">266 (25.2)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (25.3)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (25.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">451</td><td align="left" valign="top" rowspan="1" colspan="1">248 (2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (3.2)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (3.4)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (5.9)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Physical activity</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Inactive<xref rid="prp21078-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">809</td><td align="left" valign="top" rowspan="1" colspan="1">391 (3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">29 (4.2)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (4.3)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (3.2)</td><td align="left" valign="top" rowspan="1" colspan="1">64 (6.1)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (4.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Active<xref rid="prp21078-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">19&#8201;351</td><td align="left" valign="top" rowspan="1" colspan="1">11&#8201;330 (96.4)</td><td align="left" valign="top" rowspan="1" colspan="1">660 (95.1)</td><td align="left" valign="top" rowspan="1" colspan="1">198 (97.1)</td><td align="left" valign="top" rowspan="1" colspan="1">755 (95.6)</td><td align="left" valign="top" rowspan="1" colspan="1">156 (98.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1093 (96.6)</td><td align="left" valign="top" rowspan="1" colspan="1">990 (93.7)</td><td align="left" valign="top" rowspan="1" colspan="1">231 (97.5)</td><td align="left" valign="top" rowspan="1" colspan="1">65 (95.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">67</td><td align="left" valign="top" rowspan="1" colspan="1">37 (0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (0.2)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (0.2)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Alcohol consumption</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No or low<xref rid="prp21078-note-0006" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">10&#8201;839</td><td align="left" valign="top" rowspan="1" colspan="1">6263 (53.3)</td><td align="left" valign="top" rowspan="1" colspan="1">389 (56.1)</td><td align="left" valign="top" rowspan="1" colspan="1">114 (55.9)</td><td align="left" valign="top" rowspan="1" colspan="1">400 (50.6)</td><td align="left" valign="top" rowspan="1" colspan="1">83 (52.5)</td><td align="left" valign="top" rowspan="1" colspan="1">627 (55.4)</td><td align="left" valign="top" rowspan="1" colspan="1">571 (54.0)</td><td align="left" valign="top" rowspan="1" colspan="1">128 (54.0)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (48.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Moderate to frequent<xref rid="prp21078-note-0007" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">9069</td><td align="left" valign="top" rowspan="1" colspan="1">5313 (45.2)</td><td align="left" valign="top" rowspan="1" colspan="1">295 (42.5)</td><td align="left" valign="top" rowspan="1" colspan="1">86 (42.1)</td><td align="left" valign="top" rowspan="1" colspan="1">376 (47.6)</td><td align="left" valign="top" rowspan="1" colspan="1">74 (46.8)</td><td align="left" valign="top" rowspan="1" colspan="1">486 (42.9)</td><td align="left" valign="top" rowspan="1" colspan="1">470 (44.5)</td><td align="left" valign="top" rowspan="1" colspan="1">106 (44.7)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (51.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">319</td><td align="left" valign="top" rowspan="1" colspan="1">182 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (1.7)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">BMI</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">26.2 (3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">27.8 (3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">27.9 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">28.4 (4.3)</td><td align="left" valign="top" rowspan="1" colspan="1">28.7 (4.6)</td><td align="left" valign="top" rowspan="1" colspan="1">27.5 (3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">26.6 (3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">30.4 (4.7)</td><td align="left" valign="top" rowspan="1" colspan="1">31.0 (4.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">90</td><td align="left" valign="top" rowspan="1" colspan="1">47 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">5 (0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">HADS&#8208;T (HUNT2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Valid<xref rid="prp21078-note-0008" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">16&#8201;308</td><td align="left" valign="top" rowspan="1" colspan="1">9295 (79.1)</td><td align="left" valign="top" rowspan="1" colspan="1">530 (76.4)</td><td align="left" valign="top" rowspan="1" colspan="1">153 (75.0)</td><td align="left" valign="top" rowspan="1" colspan="1">646 (81.7)</td><td align="left" valign="top" rowspan="1" colspan="1">127 (80.4)</td><td align="left" valign="top" rowspan="1" colspan="1">993 (87.7)</td><td align="left" valign="top" rowspan="1" colspan="1">861 (81.5)</td><td align="left" valign="top" rowspan="1" colspan="1">190 (80.2)</td><td align="left" valign="top" rowspan="1" colspan="1">48 (70.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">6.9 (5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">7.3 (5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">6.1 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">7.3 (5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">7.0 (4.6)</td><td align="left" valign="top" rowspan="1" colspan="1">7.3 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">7.4 (5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">7.1 (5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">8.6 (5.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">3919</td><td align="left" valign="top" rowspan="1" colspan="1">2463 (15.8)</td><td align="left" valign="top" rowspan="1" colspan="1">164 (23.6)</td><td align="left" valign="top" rowspan="1" colspan="1">51 (25.0)</td><td align="left" valign="top" rowspan="1" colspan="1">144 (18.3)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (19.6)</td><td align="left" valign="top" rowspan="1" colspan="1">139 (12.3)</td><td align="left" valign="top" rowspan="1" colspan="1">196 (18.5)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (19.8)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (29.4)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">HADS&#8208;T (HUNT3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Valid<xref rid="prp21078-note-0008" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">16&#8201;542</td><td align="left" valign="top" rowspan="1" colspan="1">9577 (81.5)</td><td align="left" valign="top" rowspan="1" colspan="1">529 (76.2)</td><td align="left" valign="top" rowspan="1" colspan="1">150 (73.5)</td><td align="left" valign="top" rowspan="1" colspan="1">643 (81.4)</td><td align="left" valign="top" rowspan="1" colspan="1">131 (82.9)</td><td align="left" valign="top" rowspan="1" colspan="1">939 (82.9)</td><td align="left" valign="top" rowspan="1" colspan="1">866 (81.9)</td><td align="left" valign="top" rowspan="1" colspan="1">192 (81.0)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (69.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">6.63 (5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">6.8 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">5.7 (4.6)</td><td align="left" valign="top" rowspan="1" colspan="1">7.1 (5.3)</td><td align="left" valign="top" rowspan="1" colspan="1">7.0 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">6.7 (5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">6.8 (5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">6.6 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">7.0 (5.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">3685</td><td align="left" valign="top" rowspan="1" colspan="1">2181 (13.4)</td><td align="left" valign="top" rowspan="1" colspan="1">165 (23.8)</td><td align="left" valign="top" rowspan="1" colspan="1">54 (26.5)</td><td align="left" valign="top" rowspan="1" colspan="1">147 (18.6)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (17.1)</td><td align="left" valign="top" rowspan="1" colspan="1">193 (17.1)</td><td align="left" valign="top" rowspan="1" colspan="1">191 (18.1)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (19.0)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (30.9)</td></tr><tr><td align="left" colspan="11" valign="top" rowspan="1">Initiation of antidepressant use<xref rid="prp21078-note-0008" ref-type="table-fn">
<sup>f</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">3194</td><td align="left" valign="top" rowspan="1" colspan="1">2275 (19.3)</td><td align="left" valign="top" rowspan="1" colspan="1">73 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (12.3)</td><td align="left" valign="top" rowspan="1" colspan="1">125 (15.8)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (12.0)</td><td align="left" valign="top" rowspan="1" colspan="1">148 (13.1)</td><td align="left" valign="top" rowspan="1" colspan="1">104 (8.9)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (11.0)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (11.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">17&#8201;033</td><td align="left" valign="top" rowspan="1" colspan="1">9483 (80.7)</td><td align="left" valign="top" rowspan="1" colspan="1">621 (89.5)</td><td align="left" valign="top" rowspan="1" colspan="1">179 (87.7)</td><td align="left" valign="top" rowspan="1" colspan="1">665 (84.2)</td><td align="left" valign="top" rowspan="1" colspan="1">139 (88.0)</td><td align="left" valign="top" rowspan="1" colspan="1">984 (86.9)</td><td align="left" valign="top" rowspan="1" colspan="1">953 (91.1)</td><td align="left" valign="top" rowspan="1" colspan="1">211 (89.0)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (88.2)</td></tr></tbody></table><table-wrap-foot id="prp21078-ntgp-0001"><fn id="prp21078-note-0001"><p>Abbreviations: ACE&#8208;I, Angiotensin&#8208;converting enzyme inhibitors; ARBs, Angiotensin II receptor blockers; ASA, Acetylsalicylic acid; BB, Beta&#8208;blockers; CCB, Calcium channel blockers; HUNT, The Tr&#248;ndelag Health Study.</p></fn><fn id="prp21078-note-0002"><p>Reference&#160;=&#160;participants with no dispensed prescriptions for metformin or any cardiovascular agents included in this study.</p></fn><fn id="prp21078-note-0003"><label>
<sup>a</sup>
</label><p>SD, standard deviation.</p></fn><fn id="prp21078-note-0004"><label>
<sup>b</sup>
</label><p>Inactive&#160;=&#160;never or no light/hard physical activity per week; Light physical activity (no sweating or heavy breathing) vs. hard physical activity.</p></fn><fn id="prp21078-note-0005"><label>
<sup>c</sup>
</label><p>Active&#160;=&#160;less than once or more light/hard physical activity per week; Alcohol consumption.</p></fn><fn id="prp21078-note-0006"><label>
<sup>d</sup>
</label><p>No or low drinking&#160;=&#160;Never or &#8804;1 time/week.</p></fn><fn id="prp21078-note-0007"><label>
<sup>e</sup>
</label><p>Moderate (2&#8211;3 times/week) to frequent (&#8805;4 times/week); BMI&#160;=&#160;Body mass index (kg/m<sup>2</sup>).</p></fn><fn id="prp21078-note-0008"><label>
<sup>f</sup>
</label><p>HADS&#8208;T, Hospital Anxiety and Depression Scale&#8208;Total; Valid &#8208;HADS&#8208;T&#8208;defined by at least five answers on HADS&#8208;Anxiety (HADS&#8208;A) and HADS&#8208;Depression (HADS&#8208;D) Scales.</p></fn><fn id="prp21078-note-0009"><label>
<sup>g</sup>
</label><p>Initiation of antidepressant use &#8208;defined by the first dispensation of antidepressant agents after HUNT3.</p></fn></table-wrap-foot></table-wrap><p>Of the total, 3194 participants (15.8%) received their first antidepressant prescription during the follow&#8208;up. Table&#160;<xref rid="prp21078-tbl-0002" ref-type="table">2</xref> shows adjusted HRs with 95%CI (specified by Models 1 and 2) of antidepressant initiation according to cardiovascular agents and metformin mono or polytherapy during a 10&#8208;year follow&#8208;up. HRs adjusted for age (time&#8208;varying covariate), sex, HADS&#8208;T, and BMI (Models 2) with 95%CI of antidepressant initiation according to cardiovascular agents and metformin mono or polytherapy during a 10&#8208;year follow&#8208;up are shown in Figure&#160;<xref rid="prp21078-fig-0002" ref-type="fig">2</xref>.</p><table-wrap position="float" id="prp21078-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Adjusted Hazard Ratios (HRs) with 95% confidence interval (CI) of antidepressant initiation according to cardiovascular agents and metformin mono&#8208; or polytherapy during a 10&#160;year follow&#8208;up.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Drug class</th><th align="left" valign="bottom" rowspan="1" colspan="1">Person years</th><th align="left" valign="bottom" rowspan="1" colspan="1">Outcome/total study population</th><th align="left" valign="bottom" rowspan="1" colspan="1">Model 1</th><th align="left" valign="bottom" rowspan="1" colspan="1">Model 2</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="5" valign="top" rowspan="1">ACEI</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mono</td><td align="left" valign="top" rowspan="1" colspan="1">1876.5</td><td align="left" valign="top" rowspan="1" colspan="1">36/397</td><td align="left" valign="top" rowspan="1" colspan="1">0.70 (0.55&#8211;1.05)</td><td align="left" valign="top" rowspan="1" colspan="1">0.84 (0.59&#8211;1.20)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Poly</td><td align="left" valign="top" rowspan="1" colspan="1">1378.5</td><td align="left" valign="top" rowspan="1" colspan="1">34/267</td><td align="left" valign="top" rowspan="1" colspan="1">1.14 (0.81&#8211;1.61)</td><td align="left" valign="top" rowspan="1" colspan="1">1.07 (0.73&#8211;1.58)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1">155928.1</td><td align="left" valign="top" rowspan="1" colspan="1">2332/11758</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">ARBs</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mono</td><td align="left" valign="top" rowspan="1" colspan="1">5510.4</td><td align="left" valign="top" rowspan="1" colspan="1">101/1181</td><td align="left" valign="top" rowspan="1" colspan="1">0.73 (0.59&#8211;0.89)</td><td align="left" valign="top" rowspan="1" colspan="1">0.70 (0.56&#8211;0.88)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Poly</td><td align="left" valign="top" rowspan="1" colspan="1">1129.9</td><td align="left" valign="top" rowspan="1" colspan="1">22/217</td><td align="left" valign="top" rowspan="1" colspan="1">0.87 (0.57&#8211;1.32)</td><td align="left" valign="top" rowspan="1" colspan="1">0.77 (0.46&#8211;1.28)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">ASA</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mono</td><td align="left" valign="top" rowspan="1" colspan="1">3770.2</td><td align="left" valign="top" rowspan="1" colspan="1">109/655</td><td align="left" valign="top" rowspan="1" colspan="1">1.34 (1.10&#8211;1.64)</td><td align="left" valign="top" rowspan="1" colspan="1">1.27 (1.02&#8211;1.57)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Poly</td><td align="left" valign="top" rowspan="1" colspan="1">5713.5</td><td align="left" valign="top" rowspan="1" colspan="1">106/1054</td><td align="left" valign="top" rowspan="1" colspan="1">0.89 (0.73&#8211;1.09)</td><td align="left" valign="top" rowspan="1" colspan="1">0.85 (0.68&#8211;1.06)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">BB</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mono</td><td align="left" valign="top" rowspan="1" colspan="1">3691.3</td><td align="left" valign="top" rowspan="1" colspan="1">88/667</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (0.81&#8211;1.25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.95 (0.74&#8211;1.21)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Poly</td><td align="left" valign="top" rowspan="1" colspan="1">3248.7</td><td align="left" valign="top" rowspan="1" colspan="1">58/579</td><td align="left" valign="top" rowspan="1" colspan="1">0.89 (0.68&#8211;1.16)</td><td align="left" valign="top" rowspan="1" colspan="1">0.86 (0.64&#8211;1.15)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">CCB</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mono</td><td align="left" valign="top" rowspan="1" colspan="1">3045.8</td><td align="left" valign="top" rowspan="1" colspan="1">73/694</td><td align="left" valign="top" rowspan="1" colspan="1">0.92 (0.72&#8211;1.16)</td><td align="left" valign="top" rowspan="1" colspan="1">0.81 (0.61&#8211;1.06)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Poly</td><td align="left" valign="top" rowspan="1" colspan="1">1036.2</td><td align="left" valign="top" rowspan="1" colspan="1">25/204</td><td align="left" valign="top" rowspan="1" colspan="1">1.04 (0.70&#8211;1.55)</td><td align="left" valign="top" rowspan="1" colspan="1">1.16 (0.75&#8211;1.78)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Diuretics</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mono</td><td align="left" valign="top" rowspan="1" colspan="1">5758.8</td><td align="left" valign="top" rowspan="1" colspan="1">125/790</td><td align="left" valign="top" rowspan="1" colspan="1">1.07 (0.89&#8211;1.28)</td><td align="left" valign="top" rowspan="1" colspan="1">0.98 (0.80&#8211;1.20)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Poly</td><td align="left" valign="top" rowspan="1" colspan="1">1075.5</td><td align="left" valign="top" rowspan="1" colspan="1">19/158</td><td align="left" valign="top" rowspan="1" colspan="1">0.88 (0.56&#8211;1.39)</td><td align="left" valign="top" rowspan="1" colspan="1">0.90 (0.56&#8211;1.45)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Statins</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mono</td><td align="left" valign="top" rowspan="1" colspan="1">6209.7</td><td align="left" valign="top" rowspan="1" colspan="1">148/1132</td><td align="left" valign="top" rowspan="1" colspan="1">0.99 (0.83&#8211;1.17)</td><td align="left" valign="top" rowspan="1" colspan="1">0.95 (0.78&#8211;1.15)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Poly</td><td align="left" valign="top" rowspan="1" colspan="1">5629.1</td><td align="left" valign="top" rowspan="1" colspan="1">104/1057</td><td align="left" valign="top" rowspan="1" colspan="1">0.86 (0.70&#8211;1.06)</td><td align="left" valign="top" rowspan="1" colspan="1">0.80 (0.64&#8211;1.10)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">Metformin</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mono</td><td align="left" valign="top" rowspan="1" colspan="1">1350.6</td><td align="left" valign="top" rowspan="1" colspan="1">26/237</td><td align="left" valign="top" rowspan="1" colspan="1">0.92 (0.63&#8211;1.36)</td><td align="left" valign="top" rowspan="1" colspan="1">0.98 (0.66&#8211;1.46)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Poly</td><td align="left" valign="top" rowspan="1" colspan="1">390.4</td><td align="left" valign="top" rowspan="1" colspan="1">8/68</td><td align="left" valign="top" rowspan="1" colspan="1">0.98 (0.49&#8211;1.97)</td><td align="left" valign="top" rowspan="1" colspan="1">0.61 (0.23&#8211;1.63)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot id="prp21078-ntgp-0002"><fn id="prp21078-note-0010"><p>
<bold>Model 1:</bold> Adjusted for age as time&#8208;varying covariate and sex.</p></fn><fn id="prp21078-note-0011"><p>
<bold>Model 2:</bold> Model 1 plus adjusted for HADS&#8208;T and BMI (continuous).</p></fn><fn id="prp21078-note-0012"><p>
<bold>Reference</bold>&#160;=&#160;participants with no dispensed prescriptions of metformin or any cardiovascular agents included in this study.</p></fn><fn id="prp21078-note-0013"><p>
<bold>Outcome</bold>&#160;=&#160;the first antidepressant prescription during a 10&#8208;year follow&#8208;up.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="prp21078-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Adjusted Hazard Ratios (HRs) with 95% confidence intervals (CIs) for the initiation of antidepressant use according to cardiovascular agents and metformin mono&#8208; or polytherapy during a 10&#8208;ten year follow&#8208;up. Participants with no dispensed prescriptions for metformin or any cardiovascular agents included in this study as a reference.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PRP2-11-e01078-g002.jpg"/></fig><p>Among the study population, ARBs or CCB monotherapy was associated with a 30% and 19% lower risk (HR) of antidepressant initiation compared to no use of any drugs in the study (HR 0.70; 95%CI 0.56&#8211;0.88 and HR 0.81; 95%CI 0.61&#8211;1.06, respectively). Furthermore, ASA or statins polytherapy was associated with reduced risk of antidepressant initiation compared to reference (HR 0.85; 95%CI 0.68&#8211;1.06 and HR 0.80; 95%CI 0.64&#8211;1.10). For those using ASA as monotherapy, there was a small evaluated risk (HR 1.27; 95% CI 1.02&#8211;1.57) of antidepressant initiation. Our results showed no signs of associations between ACEI, BB, diuretics, or metformin and increased or decreased risk of initiating antidepressant use.</p></sec><sec sec-type="discussion" id="prp21078-sec-0010"><label>4</label><title>DISCUSSION</title><p>In a sample of over 20&#8201;000 community&#8208;dwelling adults, we observed mixed results regarding various classes of cardiovascular agents or metformin as a potential risk or protective factor for the initiation of antidepressant use. ARBs monotherapy and, to a lesser extent, CCB monotherapy, ASA or statin polytherapy were associated with reduced risk of the initiation of antidepressant use, while a small but elevated risk was found among ASA monotherapy users. Neither diuretics nor metformin showed any apparent association with the increased or decreased risk of initiating antidepressant use.</p><p>Our findings appear broadly aligned with observational,<xref rid="prp21078-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="prp21078-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> preclinical, and clinical<xref rid="prp21078-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="prp21078-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="prp21078-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="prp21078-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> studies suggesting a reduced risk of depression among ARB, CCB, and statin users while partially supporting epidemiological evidence of the associations between ASA and depression.<xref rid="prp21078-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="prp21078-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Consistent with our results, the Danish population&#8208;based studies showed a lower 10&#8208;year incidence of depression measured by clinical diagnosis or antidepressant prescription among continuous users (i.e., with &#8805;3 cumulative prescriptions) of ACEI, ARBs or CCB<xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> or statins<xref rid="prp21078-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> compared with individuals with 1&#8211;2 prescriptions of these drugs. In contrast, our data did not confirm associations between BB and depression found among Danish adults.<xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</p><p>The large register&#8208;based study suggested that low&#8208;dose and high&#8208;dose ASA were associated with reduced and increased incidence of depression (based on clinical diagnosis or antidepressant prescription), respectively.<xref rid="prp21078-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> These results may, to some degree, align with our data, showing the associations between ASA polytherapy and reduced risk of antidepressant initiation. However, the definition of exposures, reference group, and study design used by Kessing et al.<xref rid="prp21078-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> differ from ours, which challenges a direct comparison of findings between the studies.</p><p>Furthermore, an investigation of prescription data of over 58 million Americans aged 18&#8211;90&#8201;years showed a lower incidence of 2&#8208;year clinically diagnosed depression for individuals treated with ARBs than those with CCB (controls) but higher for those treated with BB than CCB.<xref rid="prp21078-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> A comparative analysis of ARBs and ACEI by Colbourne et al.<xref rid="prp21078-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> found that the risk of depression diagnosis was lower among ARBs users; the results support ours. There are studies suggesting CCB mechanism of action on nervous system activity through inflammation<xref rid="prp21078-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> and calcium signalling<xref rid="prp21078-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> and associations between CCB and improved outcomes among people with serious mental illnesses other than depression.<xref rid="prp21078-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> Despite the theoretical basis for the antidepressive effect of CCB, evidence that exposure to this drug may benefit depression is still minimal and inconsistent.<xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="prp21078-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="prp21078-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="prp21078-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> Considering the weak associations of the CCB monotherapy with reduced risk of antidepressant initiation, our results broadly align with these findings.</p><p>Relative to comparison groups and study design, associations of cardiovascular agents with risk of antidepressant initiation detected in our data are mixed compared with the existing literature.<xref rid="prp21078-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="prp21078-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> For example, Kessing et al.<xref rid="prp21078-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="prp21078-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> selected participants with only 1&#8211;2 drug prescriptions during follow&#8208;up as a reference to control potential confounding due to hypertension. In contrast, the reference group for each drug class analyzed in this study included participants with no prescriptions for any of the drug classes included in the study. Our findings suggest that cardiovascular agents and metformin are differently associated with risk of antidepressant initiation, with exposure to ARBs or CCB monotherapy and ASA or statin polytherapy being associated with reduced risk. These findings might be partly explained by various mechanisms of action (via the drug's anti&#8208;inflammatory or central nervous system action), possibly also by the study design and settings.</p><sec id="prp21078-sec-0011"><label>4.1</label><title>Strengths and limitations</title><p>Strengths of this study include the large population&#8208;based sample, the ability to link a health survey to EHR and the examination of several drug classes over an extended follow&#8208;up time. Given the high burden of depression among people with CVDs and DM, our study also addresses a clinically relevant topic. However, several limitations need to be considered when interpreting these results. As other population&#8208;based studies, participation in HUNT surveys is likely to select the &#171;healthier&#187; part of the adult population, where individuals with severe chronic conditions, such as CVDs, DM, depression, and anxiety symptoms, and those in hospitals and nursing homes are likely underrepresented.<xref rid="prp21078-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="prp21078-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> As a result, the frequency of risk factors for the development of CVDs, DM, and depression may be lower among individuals in this study than the random sample of adults aged 40&#8211;70&#8201;years. Hence, this selection bias may cause the true relationship between the exposure and outcome to be underestimated. Revision of clinical guidelines over the past years<xref rid="prp21078-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> has resulted in lower diagnostic and pharmacotherapy treatment thresholds for CVDs and DM,<xref rid="prp21078-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> resulting in a &#8220;generally healthier part of the population&#8221; diagnosed and treated for these diseases.<xref rid="prp21078-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> At least to some extent, such a change may have underestimated our findings.</p><p>This study selected participants with no dispensed prescriptions for cardiovascular agents, metformin, and antidepressants six months before baseline. Exploratory analysis in a previous study<xref rid="prp21078-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> and chronic drug treatments for CVDs and DM indicate that a six&#8208;month treatment&#8208;free period can be expected to have sufficient sensitivity to capture the individuals not using these drugs. By such design, participants diagnosed and treated for depression earlier in life or those on non&#8208;pharmacological depression treatments might still be included in the analysis. This limitation could be expected to influence results, possibly in the direction of underestimation. An adjustment for the HADS&#8208;T aimed to minimize the influence of the possible inclusion of participants with increased psychological symptoms at baseline in the analysis. However, this analysis did not account for change in HADS&#8208;T and BMI and other time&#8208;varying factors (e.g., psychological or physical conditions, disease severity, lifestyle) and competing risk factors (i.e., death) that could influence the findings. Due to a lack of mortality data, participants included in exposure groups in this study would have contributed with person times during the whole follow&#8208;up even if they died. Given that higher mortality is expected among participants with CVDs or DM, an underestimation of the true associations is possible.</p><p>Furthermore, physical conditions such CVDs and DM are individual risk factors for depression, where drug treatments for these comorbidities (e.g., cardiovascular or antidiabetic agents) might be a proxy for increased and decreased depression risk, influencing our results in both directions. Another challenge was distinguishing participants into mono&#8208; or polytherapy groups. We used a simplified approach and classified the study participants according to their first prescription during the follow&#8208;up, which likely overestimated the number of monotherapy users and probably reported estimates for this exposure group. Moreover, this study design could not capture changes in exposure over time (i.e., from mono&#8208; to polytherapy and vice versa, changes between drug classes or drug discontinuation), which is likely to bias our results, potentially in both directions. Because of the multiple indications for antidepressants, relying solely on antidepressant prescriptions as a proxy for depression may have misclassified the outcome. Therefore, the findings for drugs included in this study cannot be transferred directly to the diagnosis of depression. Likewise, cardiovascular agents and metformin may also have multiple indications with varying underlying depression risks, potentially influencing our findings in both directions.</p><p>All abovementioned may, to some degree, affect our findings by over&#8208;or underestimating the risk of antidepressant initiation among users of drugs included in this study. Finally, diversity in study populations, health care systems, treatment guidelines, and validity and reliability in EHRs and health survey data complicate the comparison between studies and should be considered in the generalizability of our findings.</p></sec><sec id="prp21078-sec-0012"><label>4.2</label><title>Conclusions</title><p>This study found mixed evidence regarding antidepressant initiation among users of metformin and/or various classes of cardiovascular agents as mono&#8208; or polytherapy. ARBs monotherapy use, in particular, was associated with a reduced risk of initiating antidepressant use. Ultimately, whether and to what degree these drug classes de&#8208; or increase the risk for depression should be evaluated by observational studies using methodologically robust designs, for example, self&#8208;controlled designs<xref rid="prp21078-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> or active&#8208;comparator new&#8208;user design,<xref rid="prp21078-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> and such evidence can play an important role in candidate agent selection.</p></sec></sec><sec id="prp21078-sec-0013"><title>AUTHOR CONTRIBUTIONS</title><p>All authors contributed substantially to the conceptualization, design of the study, and writing of the manuscript. IB performed statistical analysis in collaboration with JHB and ERS. All authors contributed to the interpretation of the results of the analysis. IB wrote the article's first draft, and HS, OB, LJW, MB, JHB, and ERS critically revised the content. All authors read and approved the final manuscript.</p></sec><sec id="prp21078-sec-0015"><title>FUNDING INFORMATION</title><p>This work was supported by the Faculty of Nursing and Health Sciences at Nord University, Nord. The funding source had no role in the design of the study, analysis, and interpretation of the data or writing of the manuscript.</p></sec><sec sec-type="COI-statement" id="prp21078-sec-0016"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors IB, OB, LJW, MB, JHB, ERS, and HS declare no conflict of interests regarding the content of this article.</p></sec><sec id="prp21078-sec-0019"><title>ETHICAL APPROVAL AND CONSENT TO PARTICIPATE</title><p>All HUNT participants were informed about the study and gave their informed consent to participate. The consistent included the use of the data material in the future, and it was approved by the Regional Committees for Medical Research and Health Research Ethics. This study was approved by the Regional Committees for Medical Research and Health Research Ethics in Norway (reference2019/30292/REK Nord) and the Norwegian Centre for Research Data (reference 30&#8201;292/NSD). All study methods were carried out following the institutional guidelines and according to the ethical standards in human research.</p></sec></body><back><ack id="prp21078-sec-0014"><title>ACKNOWLEDGMENTS</title><p>The Tr&#248;ndelag Health Study (The HUNT Study) is a collaboration between the HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology NTNU), Tr&#248;ndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. MB is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1156072). MB has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Abbot, Astra Zeneca, Janssen and Janssen, Lundbeck and Merck and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Janssen and Janssen, Lundbeck Merck, Pfizer and Servier&#8212;all unrelated to this work. LJW is supported by NHMRC Emerging Leadership Fellowship (1174060). LJW has received Grant/Research support from Eli Lilly, Pfizer, The University of Melbourne, Deakin University, NHMRC and the Medical Research Future Fund (MRFF) Australia&#8212;all unrelated to this work.</p></ack><sec sec-type="data-availability" id="prp21078-sec-0018"><title>DATA AVAILABILITY STATEMENT</title><p>The data used in this study are available from the HUNT databank, but restrictions apply to the availability of these data. The data were used under license for the current study and so are not publicly available. However, data are available from the authors upon reasonable request and with permission from the HUNT, The Regional Ethical Committee, and Norwegian Data Protection Authority. The dataset used in this study is stored in HUNT databank using a personal identification number given to all Norwegians at birth or immigration as a key identification. The HUNT Research Centre has permission from the Norwegian Data Inspectorate to store and handle these data. The HUNT data are available for scientists who wish to use them for research and non&#8208;commercial purposes without breaching participant confidentiality. The researcher will always receive an anonymous or &#8220;de&#8208;identified&#8221; dataset after receiving approval of a research protocol by the Regional Ethical Committee and HUNT Research Centre. To protect participants' privacy, HUNT Research Centre aims to limit data storage outside the HUNT databank and cannot deposit data in open repositories. HUNT databank has precise information on all data exported to different projects and can reproduce these on request. There are no restrictions regarding data export to give approval of applications to HUNT Research. For more information about HUNT data, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ntnu.edu/hunt/data" ext-link-type="uri" specific-use="software is-supplemented-by">https://www.ntnu.edu/hunt/data</ext-link>.</p></sec><ref-list content-type="cited-references" id="prp21078-bibl-0001"><title>REFERENCES</title><ref id="prp21078-bib-0001"><label>1</label><mixed-citation publication-type="book" id="prp21078-cit-0001"><part-title>Mental illness among adults in Norway</part-title>. <source>Public Health Report &#8208; Health Status in Norway [Online Document]</source>. <publisher-name>Institute of Public Health</publisher-name>, 2016 [updated 08 August 2016]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fhi.no/en/op/hin/mental-health/psykisk-helse-hos-voksne/" ext-link-type="uri">https://www.fhi.no/en/op/hin/mental&#8208;health/psykisk&#8208;helse&#8208;hos&#8208;voksne/</ext-link>.</mixed-citation></ref><ref id="prp21078-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="prp21078-cit-0002"><string-name name-style="western"><surname>Bojani&#263;</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sund</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Sletvold</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bjerkeset</surname><given-names>O</given-names></string-name>. <article-title>Prevalence trends of depression and anxiety symptoms in adults with cardiovascular diseases and diabetes 1995&#8211;2019: the HUNT studies</article-title>. <source>Norway BMC Psychology</source>. <year>2021</year>;<volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>16</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40359-021-00636-0</pub-id><pub-id pub-id-type="pmcid">PMC8406588</pub-id><pub-id pub-id-type="pmid">34465377</pub-id></mixed-citation></ref><ref id="prp21078-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="prp21078-cit-0003"><string-name name-style="western"><surname>Yu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>. <article-title>Trends in depression among adults in the United States, NHANES 2005&#8211;2016</article-title>. <source>J Affect Disord</source>. <year>2020</year>;<volume>263</volume>:<fpage>609</fpage>&#8208;<lpage>620</lpage>.<pub-id pub-id-type="pmid">31744739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2019.11.036</pub-id></mixed-citation></ref><ref id="prp21078-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="prp21078-cit-0004"><string-name name-style="western"><surname>Bretschneider</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Janitza</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jacobi</surname><given-names>F</given-names></string-name>, et al. <article-title>Time trends in depression prevalence and health&#8208;related correlates: results from population&#8208;based surveys in Germany 1997&#8211;1999 vs. 2009&#8211;2012</article-title>. <source>BMC Psychiatry</source>. <year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>394</fpage>.<pub-id pub-id-type="pmid">30572872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12888-018-1973-7</pub-id><pub-id pub-id-type="pmcid">PMC6302526</pub-id></mixed-citation></ref><ref id="prp21078-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="prp21078-cit-0005"><string-name name-style="western"><surname>Roy</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lloyd</surname><given-names>CE</given-names></string-name>. <article-title>Epidemiology of depression and diabetes: a systematic review</article-title>. <source>J Affect Disord</source>. <year>2012</year>;<volume>142</volume>:<fpage>S8</fpage>&#8208;<lpage>S21</lpage>.<pub-id pub-id-type="pmid">23062861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0165-0327(12)70004-6</pub-id></mixed-citation></ref><ref id="prp21078-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="prp21078-cit-0006"><string-name name-style="western"><surname>Chobufo</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Agbor</surname><given-names>VN</given-names></string-name>, et al. <article-title>10&#8208;year trend in the prevalence and predictors of depression among patients with heart failure in the USA from 2007&#8211;2016</article-title>. <source>Int J Cardiol</source>. <year>2020</year>;<volume>301</volume>:<fpage>123</fpage>&#8208;<lpage>126</lpage>.<pub-id pub-id-type="pmid">31757653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2019.09.028</pub-id></mixed-citation></ref><ref id="prp21078-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="prp21078-cit-0007"><string-name name-style="western"><surname>Ghaemmohamadi</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Behzadifar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ghashghaee</surname><given-names>A</given-names></string-name>, et al. <article-title>Prevalence of depression in cardiovascular patients in Iran: a systematic review and meta&#8208;analysis from 2000 to 2017</article-title>. <source>J Affect Disord</source>. <year>2018</year>;<volume>227</volume>:<fpage>149</fpage>&#8208;<lpage>155</lpage>.<pub-id pub-id-type="pmid">29073577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2017.10.026</pub-id></mixed-citation></ref><ref id="prp21078-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="prp21078-cit-0008"><string-name name-style="western"><surname>Ormel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Von Korff</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Burger</surname><given-names>H</given-names></string-name>, et al. <article-title>Mental disorders among persons with heart disease &#8212; results from world mental health surveys</article-title>. <source>Gen Hosp Psychiatry</source>. <year>2007</year>;<volume>29</volume>(<issue>4</issue>):<fpage>325</fpage>&#8208;<lpage>334</lpage>.<pub-id pub-id-type="pmid">17591509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.genhosppsych.2007.03.009</pub-id><pub-id pub-id-type="pmcid">PMC2048744</pub-id></mixed-citation></ref><ref id="prp21078-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="prp21078-cit-0009"><string-name name-style="western"><surname>Lin</surname><given-names>EHB</given-names></string-name>, <string-name name-style="western"><surname>Von Korff</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alonso</surname><given-names>J</given-names></string-name>, et al. <article-title>Mental disorders among persons with diabetes&#8208;&#8208;results from the world mental health surveys</article-title>. <source>J Psychosom Res</source>. <year>2008</year>;<volume>65</volume>(<issue>6</issue>):<fpage>571</fpage>&#8208;<lpage>580</lpage>. Mental disorders among persons with diabetes&#8212;Results from the World Mental Health Surveys.<pub-id pub-id-type="pmid">19027447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychores.2008.06.007</pub-id><pub-id pub-id-type="pmcid">PMC3672403</pub-id></mixed-citation></ref><ref id="prp21078-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="prp21078-cit-0010"><string-name name-style="western"><surname>Mago</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tripathi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Andrade</surname><given-names>C</given-names></string-name>. <article-title>Cardiovascular adverse effects of newer antidepressants</article-title>. <source>Expert Rev Neurother</source>. <year>2014</year>;<volume>14</volume>(<issue>5</issue>):<fpage>539</fpage>&#8208;<lpage>551</lpage>.<pub-id pub-id-type="pmid">24738823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14737175.2014.908709</pub-id></mixed-citation></ref><ref id="prp21078-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="prp21078-cit-0011"><string-name name-style="western"><surname>McIntyre</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>KY</given-names></string-name>, <string-name name-style="western"><surname>Law</surname><given-names>CWY</given-names></string-name>, et al. <article-title>The association between conventional antidepressants and the metabolic syndrome</article-title>. <source>CNS Drugs</source>. <year>2010</year>;<volume>24</volume>(<issue>9</issue>):<fpage>741</fpage>&#8208;<lpage>753</lpage>.<pub-id pub-id-type="pmid">20806987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11533280-000000000-00000</pub-id></mixed-citation></ref><ref id="prp21078-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="prp21078-cit-0012"><string-name name-style="western"><surname>Khawam</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Laurencic</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Malone</surname><given-names>DA</given-names><suffix>Jr</suffix></string-name>. <article-title>Side effects of antidepressants: an overview</article-title>. <source>Cleve Clin J Med</source>. <year>2006</year>;<volume>73</volume>(<issue>4</issue>):<fpage>351</fpage>&#8208;<lpage>353</lpage>. 356&#8211;61.<pub-id pub-id-type="pmid">16610395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3949/ccjm.73.4.351</pub-id></mixed-citation></ref><ref id="prp21078-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="prp21078-cit-0013"><string-name name-style="western"><surname>Kennedy</surname><given-names>SH</given-names></string-name>. <article-title>A review of antidepressant therapy in primary care: current practices and future directions</article-title>. <source>The Primary Care Companion for CNS Disorders</source>. <year>2013</year>;<volume>15</volume>(<issue>2</issue>):<fpage>23071</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/PCC.12r01420</pub-id><pub-id pub-id-type="pmcid">PMC3733527</pub-id><pub-id pub-id-type="pmid">23930234</pub-id></mixed-citation></ref><ref id="prp21078-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="prp21078-cit-0014"><string-name name-style="western"><surname>Sidor</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>MacQueen</surname><given-names>GM</given-names></string-name>. <article-title>Antidepressants for the acute treatment of bipolar depression: a systematic review and meta&#8208;analysis</article-title>. <source>J Clin Psychiatry</source>. <year>2010</year>;<volume>71</volume>(<issue>2</issue>):<fpage>953</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/JCP.09r05385gre</pub-id><pub-id pub-id-type="pmid">21034686</pub-id></mixed-citation></ref><ref id="prp21078-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="prp21078-cit-0015"><string-name name-style="western"><surname>Blackburn</surname><given-names>TP</given-names></string-name>. <article-title>Depressive disorders: treatment failures and poor prognosis over the last 50&#8201;years</article-title>. <source>Pharmacol Res Perspect</source>. <year>2019</year>;<volume>7</volume>(<issue>3</issue>):<elocation-id>e00472</elocation-id>.<pub-id pub-id-type="pmid">31065377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prp2.472</pub-id><pub-id pub-id-type="pmcid">PMC6498411</pub-id></mixed-citation></ref><ref id="prp21078-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="prp21078-cit-0016"><string-name name-style="western"><surname>Pushpakom</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Iorio</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Eyers</surname><given-names>PA</given-names></string-name>, et al. <article-title>Drug repurposing: progress, challenges and recommendations</article-title>. <source>Nat Rev Drug Discov</source>. <year>2019</year>;<volume>18</volume>(<issue>1</issue>):<fpage>41</fpage>&#8208;<lpage>58</lpage>.<pub-id pub-id-type="pmid">30310233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2018.168</pub-id></mixed-citation></ref><ref id="prp21078-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="prp21078-cit-0017"><string-name name-style="western"><surname>Miller</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Raison</surname><given-names>CL</given-names></string-name>. <article-title>The role of inflammation in depression: from evolutionary imperative to modern treatment target</article-title>. <source>Nat Rev Immunol</source>. <year>2016</year>;<volume>16</volume>(<issue>1</issue>):<fpage>22</fpage>&#8208;<lpage>34</lpage>.<pub-id pub-id-type="pmid">26711676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri.2015.5</pub-id><pub-id pub-id-type="pmcid">PMC5542678</pub-id></mixed-citation></ref><ref id="prp21078-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="prp21078-cit-0018"><string-name name-style="western"><surname>Vian</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chavarria</surname><given-names>V</given-names></string-name>, et al. <article-title>The renin&#8208;angiotensin system: a possible new target for depression</article-title>. <source>BMC Med</source>. <year>2017</year>;<volume>15</volume>(<issue>1</issue>):<fpage>144</fpage>.<pub-id pub-id-type="pmid">28760142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-017-0916-3</pub-id><pub-id pub-id-type="pmcid">PMC5537940</pub-id></mixed-citation></ref><ref id="prp21078-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="prp21078-cit-0019"><string-name name-style="western"><surname>El Massry</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alaeddine</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Saad</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Eid</surname><given-names>AA</given-names></string-name>. <article-title>Metformin: a growing journey from glycemic control to the treatment of Alzheimer's disease and depression</article-title>. <source>Curr Med Chem</source>. <year>2021</year>;<volume>28</volume>(<issue>12</issue>):<fpage>2328</fpage>&#8208;<lpage>2345</lpage>.<pub-id pub-id-type="pmid">32900343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867327666200908114902</pub-id></mixed-citation></ref><ref id="prp21078-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="prp21078-cit-0020"><string-name name-style="western"><surname>Penninx</surname><given-names>BWJH</given-names></string-name>. <article-title>Depression and cardiovascular disease: epidemiological evidence on their linking mechanisms</article-title>. <source>Neuroscience &amp; Biobehavioral Reviews</source>. <year>2017</year>;<volume>74</volume>:<fpage>277</fpage>&#8208;<lpage>286</lpage>.<pub-id pub-id-type="pmid">27461915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2016.07.003</pub-id></mixed-citation></ref><ref id="prp21078-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="prp21078-cit-0021"><string-name name-style="western"><surname>Grigolon</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Brietzke</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mansur</surname><given-names>RB</given-names></string-name>, et al. <article-title>Association between diabetes and mood disorders and the potential use of anti&#8208;hyperglycemic agents as antidepressants</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source>. <year>2019</year>;<volume>95</volume>:<elocation-id>109720</elocation-id>.<pub-id pub-id-type="pmid">31352032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pnpbp.2019.109720</pub-id></mixed-citation></ref><ref id="prp21078-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="prp21078-cit-0022"><string-name name-style="western"><surname>Kessing</surname><given-names>LV</given-names></string-name>, <string-name name-style="western"><surname>Rytgaard</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Gerds</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Berk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ekstr&#248;m</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>PK</given-names></string-name>. <article-title>New drug candidates for depression &#8208; a nationwide population&#8208;based study</article-title>. <source>Acta Psychiatr Scand</source>. <year>2019</year>;<volume>139</volume>(<issue>1</issue>):<fpage>68</fpage>&#8208;<lpage>77</lpage>.<pub-id pub-id-type="pmid">30182363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acps.12957</pub-id></mixed-citation></ref><ref id="prp21078-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="prp21078-cit-0023"><string-name name-style="western"><surname>Kessing</surname><given-names>LV</given-names></string-name>, <string-name name-style="western"><surname>Rytgaard</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Ekstr&#248;m</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Torp&#8208;Pedersen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Berk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gerds</surname><given-names>TA</given-names></string-name>. <article-title>Antihypertensive drugs and risk of depression: a nationwide population&#8208;based study</article-title>. <source>Hypertension</source>. <year>2020</year>;<volume>76</volume>(<issue>4</issue>):<fpage>1263</fpage>&#8208;<lpage>1279</lpage>.<pub-id pub-id-type="pmid">32829669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.120.15605</pub-id></mixed-citation></ref><ref id="prp21078-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="prp21078-cit-0024"><string-name name-style="western"><surname>De Giorgi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>De Crescenzo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rizzo Pesci</surname><given-names>N</given-names></string-name>, et al. <article-title>Statins for major depressive disorder: a systematic review and meta&#8208;analysis of randomized controlled trials</article-title>. <source>PloS One</source>. <year>2021</year>;<volume>16</volume>(<issue>3</issue>):<elocation-id>e0249409</elocation-id>.<pub-id pub-id-type="pmid">33784356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0249409</pub-id><pub-id pub-id-type="pmcid">PMC8009386</pub-id></mixed-citation></ref><ref id="prp21078-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="prp21078-cit-0025"><string-name name-style="western"><surname>Tao</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>XQ</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>MY</given-names></string-name>. <article-title>Association between common cardiovascular drugs and depression</article-title>. <source>Chin Med J (Engl)</source>. <year>2021</year>;<volume>134</volume>(<issue>22</issue>):<fpage>2656</fpage>&#8208;<lpage>2665</lpage>.<pub-id pub-id-type="pmid">34759230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000001875</pub-id><pub-id pub-id-type="pmcid">PMC8631412</pub-id></mixed-citation></ref><ref id="prp21078-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="prp21078-cit-0026"><string-name name-style="western"><surname>De Giorgi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rizzo Pesci</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Quinton</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>De Crescenzo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cowen</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Harmer</surname><given-names>CJ</given-names></string-name>. <article-title>Statins in depression: an evidence&#8208;based overview of mechanisms and clinical studies. Frontiers</article-title>. <source>Psychiatry</source>. <year>2021</year>;<volume>12</volume>(<issue>1250</issue>):<fpage>1</fpage>&#8208;<lpage>24</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2021.702617</pub-id><pub-id pub-id-type="pmcid">PMC8353114</pub-id><pub-id pub-id-type="pmid">34385939</pub-id></mixed-citation></ref><ref id="prp21078-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="prp21078-cit-0027"><string-name name-style="western"><surname>Kessing</surname><given-names>LV</given-names></string-name>, <string-name name-style="western"><surname>Rytgaard</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Ekstr&#248;m</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Knop</surname><given-names>FK</given-names></string-name>, <string-name name-style="western"><surname>Berk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gerds</surname><given-names>TA</given-names></string-name>. <article-title>Antidiabetes agents and incident depression: a Nationwide population&#8208;based study</article-title>. <source>Diabetes Care</source>. <year>2020</year>;<volume>43</volume>(<issue>12</issue>):<fpage>3050</fpage>&#8208;<lpage>3060</lpage>.<pub-id pub-id-type="pmid">32978179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc20-1561</pub-id></mixed-citation></ref><ref id="prp21078-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="prp21078-cit-0028"><string-name name-style="western"><surname>Woo</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Bahk</surname><given-names>WM</given-names></string-name>. <article-title>Clinical evidence of antidepressant effects of insulin and anti&#8208;hyperglycemic agents and implications for the pathophysiology of depression&#8208;a literature review</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>18</issue>):<fpage>6969</fpage>.<pub-id pub-id-type="pmid">32971941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21186969</pub-id><pub-id pub-id-type="pmcid">PMC7554794</pub-id></mixed-citation></ref><ref id="prp21078-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="prp21078-cit-0029"><string-name name-style="western"><surname>Chen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Risk factors for depression in elderly diabetic patients and the effect of metformin on the condition</article-title>. <source>BMC Public Health</source>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>1063</fpage>.<pub-id pub-id-type="pmid">31391021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-019-7392-y</pub-id><pub-id pub-id-type="pmcid">PMC6686369</pub-id></mixed-citation></ref><ref id="prp21078-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="prp21078-cit-0030"><string-name name-style="western"><surname>Kim</surname><given-names>H&#8208;B</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J&#8208;S</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>J&#8208;G</given-names></string-name>. <article-title>The association between aspirin use and depression: a systematic review and meta&#8208;analysis of observational studies</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2020</year>;<volume>29</volume>(<issue>6</issue>):<fpage>613</fpage>&#8208;<lpage>622</lpage>.<pub-id pub-id-type="pmid">32311192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pds.5011</pub-id></mixed-citation></ref><ref id="prp21078-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="prp21078-cit-0031"><string-name name-style="western"><surname>Moulton</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Hopkins</surname><given-names>CWP</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Stahl</surname><given-names>D</given-names></string-name>. <article-title>Repositioning of diabetes treatments for depressive symptoms: a systematic review and meta&#8208;analysis of clinical trials</article-title>. <source>Psychoneuroendocrinology</source>. <year>2018</year>;<volume>94</volume>:<fpage>91</fpage>&#8208;<lpage>103</lpage>.<pub-id pub-id-type="pmid">29775878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2018.05.010</pub-id></mixed-citation></ref><ref id="prp21078-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="prp21078-cit-0032"><string-name name-style="western"><surname>Shaw</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Mackay</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pell</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Padmanabhan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>DJ</given-names></string-name>. <article-title>The relationship between antihypertensive medications and mood disorders: analysis of linked healthcare data for 1.8 million patients</article-title>. <source>Psychol Med</source>. <year>2021</year>;<volume>51</volume>(<issue>7</issue>):<fpage>1183</fpage>&#8208;<lpage>1191</lpage>.<pub-id pub-id-type="pmid">31973782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291719004094</pub-id><pub-id pub-id-type="pmcid">PMC8188528</pub-id></mixed-citation></ref><ref id="prp21078-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="prp21078-cit-0033"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Alolga</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>G</given-names></string-name>. <article-title>Antihypertensive drug use and the risk of depression: a systematic review and network meta&#8208;analysis</article-title>. <source>Front Pharmacol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>777987</elocation-id>.<pub-id pub-id-type="pmid">34819866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.777987</pub-id><pub-id pub-id-type="pmcid">PMC8606787</pub-id></mixed-citation></ref><ref id="prp21078-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="prp21078-cit-0034"><string-name name-style="western"><surname>Colbourne</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Luciano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Harrison</surname><given-names>PJ</given-names></string-name>. <article-title>Onset and recurrence of psychiatric disorders associated with anti&#8208;hypertensive drug classes</article-title>. <source>Transl Psychiatry</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>319</fpage>.<pub-id pub-id-type="pmid">34039956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-021-01444-1</pub-id><pub-id pub-id-type="pmcid">PMC8155006</pub-id></mixed-citation></ref><ref id="prp21078-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="prp21078-cit-0035"><string-name name-style="western"><surname>Yatham</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Yatham</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Ravindran</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Sullivan</surname><given-names>F</given-names></string-name>. <article-title>Do statins have an effect on depressive symptoms? A systematic review and meta&#8208;analysis</article-title>. <source>J Affect Disord</source>. <year>2019</year>;<volume>257</volume>:<fpage>55</fpage>&#8208;<lpage>63</lpage>.<pub-id pub-id-type="pmid">31299405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2019.07.002</pub-id></mixed-citation></ref><ref id="prp21078-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="prp21078-cit-0036"><string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Q</given-names></string-name>. <article-title>Electronic health Records for Drug Repurposing: current status, challenges, and future directions</article-title>. <source>Clinical Pharmacology &amp; Therapeutics</source>. <year>2020</year>;<volume>107</volume>(<issue>4</issue>):<fpage>712</fpage>&#8208;<lpage>714</lpage>.<pub-id pub-id-type="pmid">32012237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1769</pub-id><pub-id pub-id-type="pmcid">PMC10815929</pub-id></mixed-citation></ref><ref id="prp21078-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="prp21078-cit-0037"><string-name name-style="western"><surname>&#197;svold</surname><given-names>BO</given-names></string-name>, <string-name name-style="western"><surname>Langhammer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rehn</surname><given-names>TA</given-names></string-name>, et al. <article-title>Cohort profile update: the HUNT study, Norway</article-title>. <source>medRxiv</source>. <year>2021</year>;<volume>52</volume>(<issue>1</issue>):<elocation-id>e80&#8208;e91</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyac095</pub-id><pub-id pub-id-type="pmcid">PMC9908054</pub-id><pub-id pub-id-type="pmid">35578897</pub-id></mixed-citation></ref><ref id="prp21078-bib-0038"><label>38</label><mixed-citation publication-type="miscellaneous" id="prp21078-cit-0038"><collab collab-type="authors">HUNT Databank [Internet]</collab>
. <article-title>[cited 10 Oct 2020]</article-title>. Available from: <year>2021</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://hunt-db.medisin.ntnu.no/hunt-db/" ext-link-type="uri">https://hunt&#8208;db.medisin.ntnu.no/hunt&#8208;db/</ext-link></mixed-citation></ref><ref id="prp21078-bib-0039"><label>39</label><mixed-citation publication-type="miscellaneous" id="prp21078-cit-0039"><collab collab-type="authors">WHO Collaborating Centre for Drug Statistics Methodology [Internet]</collab>
. <year>2021</year>. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/medicines/regulation/medicines-safety/about/collab-centres-norwegian/en/" ext-link-type="uri">https://www.who.int/medicines/regulation/medicines&#8208;safety/about/collab&#8208;centres&#8208;norwegian/en/</ext-link>.</mixed-citation></ref><ref id="prp21078-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="prp21078-cit-0040"><string-name name-style="western"><surname>Furu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wettermark</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Martikainen</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Almarsdottir</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>S&#248;rensen</surname><given-names>HT</given-names></string-name>. <article-title>The Nordic countries as a cohort for Pharmacoepidemiological research</article-title>. <source>Basic Clin Pharmacol Toxicol</source>. <year>2010</year>;<volume>106</volume>(<issue>2</issue>):<fpage>86</fpage>&#8208;<lpage>94</lpage>.<pub-id pub-id-type="pmid">19961477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-7843.2009.00494.x</pub-id></mixed-citation></ref><ref id="prp21078-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="prp21078-cit-0041"><string-name name-style="western"><surname>Stafford</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Berk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>HJ</given-names></string-name>. <article-title>Validity of the hospital anxiety and depression scale and patient health Questionnaire&#8208;9 to screen for depression in patients with coronary artery disease</article-title>. <source>Gen Hosp Psychiatry</source>. <year>2007</year>;<volume>29</volume>(<issue>5</issue>):<fpage>417</fpage>&#8208;<lpage>424</lpage>.<pub-id pub-id-type="pmid">17888808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.genhosppsych.2007.06.005</pub-id></mixed-citation></ref><ref id="prp21078-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="prp21078-cit-0042"><string-name name-style="western"><surname>Sultan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Luminet</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Hartemann</surname><given-names>A</given-names></string-name>. <article-title>Cognitive and anxiety symptoms in screening for clinical depression in diabetes a systematic examination of diagnostic performances of the HADS and BDI&#8208;SF</article-title>. <source>J Affect Disord</source>. <year>2010</year>;<volume>123</volume>(<issue>1</issue>):<fpage>332</fpage>&#8208;<lpage>336</lpage>.<pub-id pub-id-type="pmid">19861228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2009.09.022</pub-id></mixed-citation></ref><ref id="prp21078-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="prp21078-cit-0043"><string-name name-style="western"><surname>Hess</surname><given-names>KR</given-names></string-name>. <article-title>Graphical methods for assessing violations of the proportional hazards assumption in cox regression</article-title>. <source>Stat Med</source>. <year>1995</year>;<volume>14</volume>(<issue>15</issue>):<fpage>1707</fpage>&#8208;<lpage>1723</lpage>.<pub-id pub-id-type="pmid">7481205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.4780141510</pub-id></mixed-citation></ref><ref id="prp21078-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="prp21078-cit-0044"><string-name name-style="western"><surname>Therneau</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Grambsch</surname><given-names>PM</given-names></string-name>. <article-title>Proportional hazards tests and diagnostics based on weighted residuals</article-title>. <source>Biometrika</source>. <year>1994</year>;<volume>81</volume>(<issue>3</issue>):<fpage>515</fpage>&#8208;<lpage>526</lpage>.</mixed-citation></ref><ref id="prp21078-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="prp21078-cit-0045"><string-name name-style="western"><surname>Walker</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Borissiouk</surname><given-names>I</given-names></string-name>, et al. <article-title>Statins: neurobiological underpinnings and mechanisms in mood disorders</article-title>. <source>Neuroscience &amp; Biobehavioral Reviews.</source><year>2021</year>;<volume>128</volume>:<fpage>693</fpage>&#8208;<lpage>708</lpage>.<pub-id pub-id-type="pmid">34265321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2021.07.012</pub-id></mixed-citation></ref><ref id="prp21078-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="prp21078-cit-0046"><string-name name-style="western"><surname>Brownstein</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Salagre</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>K&#246;hler</surname><given-names>C</given-names></string-name>, et al. <article-title>Blockade of the angiotensin system improves mental health domain of quality of life: a meta&#8208;analysis of randomized clinical trials</article-title>. <source>Australian &amp; New Zealand Journal of Psychiatry</source>. <year>2018</year>;<volume>52</volume>(<issue>1</issue>):<fpage>24</fpage>&#8208;<lpage>38</lpage>.<pub-id pub-id-type="pmid">28754072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0004867417721654</pub-id></mixed-citation></ref><ref id="prp21078-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="prp21078-cit-0047"><string-name name-style="western"><surname>Bergantin</surname><given-names>LB</given-names></string-name>. <article-title>The interactions between Alzheimer's disease and major depression: role of Ca(2+) channel blockers and Ca(2+)/cAMP Signalling</article-title>. <source>Curr Drug Res Rev</source>. <year>2020</year>;<volume>12</volume>(<issue>2</issue>):<fpage>97</fpage>&#8208;<lpage>102</lpage>.<pub-id pub-id-type="pmid">32065096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/2589977512666200217093356</pub-id></mixed-citation></ref><ref id="prp21078-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="prp21078-cit-0048"><string-name name-style="western"><surname>Saddala</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Lennikov</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mukwaya</surname><given-names>A</given-names></string-name>, et al. <article-title>Discovery of novel L&#8208;type voltage&#8208;gated calcium channel blockers and application for the prevention of inflammation and angiogenesis</article-title>. <source>J Neuroinflammation</source>. <year>2020</year>;<volume>17</volume>(<issue>1</issue>):<fpage>132</fpage>.<pub-id pub-id-type="pmid">32334630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-020-01801-9</pub-id><pub-id pub-id-type="pmcid">PMC7183139</pub-id></mixed-citation></ref><ref id="prp21078-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="prp21078-cit-0049"><string-name name-style="western"><surname>Andrade</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brennecke</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mallat</surname><given-names>S</given-names></string-name>, et al. <article-title>Genetic associations between voltage&#8208;gated calcium channels and psychiatric disorders</article-title>. <source>Int J Mol Sci</source>. <year>2019</year>;<volume>20</volume>(<issue>14</issue>):<fpage>3537</fpage>.<pub-id pub-id-type="pmid">31331039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20143537</pub-id><pub-id pub-id-type="pmcid">PMC6679227</pub-id></mixed-citation></ref><ref id="prp21078-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="prp21078-cit-0050"><string-name name-style="western"><surname>Hayes</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Lundin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wicks</surname><given-names>S</given-names></string-name>, et al. <article-title>Association of Hydroxylmethyl Glutaryl Coenzyme a Reductase Inhibitors, L&#8208;type Calcium Channel antagonists, and Biguanides with rates of psychiatric hospitalization and self&#8208;harm in individuals with serious mental illness</article-title>. <source>JAMA Psychiat</source>. <year>2019</year>;<volume>76</volume>(<issue>4</issue>):<fpage>382</fpage>&#8208;<lpage>390</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2018.3907</pub-id><pub-id pub-id-type="pmcid">PMC6450278</pub-id><pub-id pub-id-type="pmid">30624557</pub-id></mixed-citation></ref><ref id="prp21078-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="prp21078-cit-0051"><string-name name-style="western"><surname>Agustini</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mohebbi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Woods</surname><given-names>RL</given-names></string-name>, et al. <article-title>The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross&#8208;sectional study</article-title>. <source>J Hum Hypertens</source>. <year>2020</year>;<volume>34</volume>(<issue>11</issue>):<fpage>787</fpage>&#8208;<lpage>794</lpage>.<pub-id pub-id-type="pmid">32001828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41371-020-0303-y</pub-id><pub-id pub-id-type="pmcid">PMC7390661</pub-id></mixed-citation></ref><ref id="prp21078-bib-0052"><label>52</label><mixed-citation publication-type="miscellaneous" id="prp21078-cit-0052"><string-name name-style="western"><surname>&#197;svold</surname><given-names>BO</given-names></string-name>, <string-name name-style="western"><surname>Langhammer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rehn</surname><given-names>TA</given-names></string-name>, et al. <article-title>Cohort Profile Update: The HUNT Study, Norway 2022 [cited dyac095]</article-title>. Available from <pub-id pub-id-type="doi">10.1093/ije/dyac095</pub-id><pub-id pub-id-type="pmcid">PMC9908054</pub-id><pub-id pub-id-type="pmid">35578897</pub-id></mixed-citation></ref><ref id="prp21078-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="prp21078-cit-0053"><string-name name-style="western"><surname>Langhammer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Krokstad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Romundstad</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Heggland</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Holmen</surname><given-names>J</given-names></string-name>. <article-title>The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms</article-title>. <source>BMC Med Res Methodol</source>. <year>2012</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>14</lpage>.<pub-id pub-id-type="pmid">22978749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2288-12-143</pub-id><pub-id pub-id-type="pmcid">PMC3512497</pub-id></mixed-citation></ref><ref id="prp21078-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="prp21078-cit-0054"><collab collab-type="authors">Povl Munk&#8208;J&#248;rgensen ABAADKLELKT</collab>
. <article-title>Implementation of ICD&#8208;10 in the Nordic countries</article-title>. <source>Nord J Psychiatry</source>. <year>1999</year>;<volume>53</volume>(<issue>1</issue>):<fpage>5</fpage>&#8208;<lpage>9</lpage>.</mixed-citation></ref><ref id="prp21078-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="prp21078-cit-0055"><string-name name-style="western"><surname>Ellis</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>C</given-names></string-name>, et al. <article-title>Diagnostic category prevalence in 3 classification systems across the transition to the international classification of diseases</article-title>. <source>Tenth Revision, Clinical Modification JAMA Network Open</source>. <year>2020</year>;<volume>3</volume>(<issue>4</issue>):<fpage>e202280</fpage>.<pub-id pub-id-type="pmid">32267514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.2280</pub-id><pub-id pub-id-type="pmcid">PMC7142382</pub-id></mixed-citation></ref><ref id="prp21078-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="prp21078-cit-0056"><collab collab-type="authors">Decode Study Group obotEDESG</collab>
. <article-title>Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE study group on behalf of the European diabetes epidemiology study group</article-title>. <source>BMJ (Clinical Research Ed)</source>. <year>1998</year>;<volume>317</volume>(<issue>7155</issue>):<fpage>371</fpage>&#8208;<lpage>375</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.317.7155.371</pub-id><pub-id pub-id-type="pmcid">PMC28629</pub-id><pub-id pub-id-type="pmid">9694750</pub-id></mixed-citation></ref><ref id="prp21078-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="prp21078-cit-0057"><string-name name-style="western"><surname>Bojani&#263;</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bjerkeset</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Berk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sund</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Sletvold</surname><given-names>H</given-names></string-name>. <article-title>Associations of cardiovascular agents and metformin with depression symptoms: a cross&#8208;sectional analysis from the HUNT study</article-title>. <source>Norway Drugs &#8208; Real World Outcomes</source>. <year>2022</year>;<volume>9</volume>(<issue>3</issue>):<fpage>503</fpage>&#8208;<lpage>516</lpage>.<pub-id pub-id-type="pmid">35856136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40801-022-00321-7</pub-id><pub-id pub-id-type="pmcid">PMC9392672</pub-id></mixed-citation></ref><ref id="prp21078-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="prp21078-cit-0058"><string-name name-style="western"><surname>Petersen</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Douglas</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Whitaker</surname><given-names>H</given-names></string-name>. <article-title>Self controlled case series methods: an alternative to standard epidemiological study designs</article-title>. <source>BMJ</source>. <year>2016</year>;<volume>354</volume>:<elocation-id>i4515</elocation-id>.<pub-id pub-id-type="pmid">27618829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.i4515</pub-id></mixed-citation></ref><ref id="prp21078-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="prp21078-cit-0059"><string-name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Solomon</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SC</given-names></string-name>. <article-title>Active&#8208;comparator design and new&#8208;user design in observational studies</article-title>. <source>Nat Rev Rheumatol</source>. <year>2015</year>;<volume>11</volume>(<issue>7</issue>):<fpage>437</fpage>&#8208;<lpage>441</lpage>.<pub-id pub-id-type="pmid">25800216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrrheum.2015.30</pub-id><pub-id pub-id-type="pmcid">PMC4486631</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>